Chapter 1: Clinical Sleep Medicine and Circadian Translation

Chapter Introduction

The Cat has waited with you a long way.

In K-12 you learned why sleep exists. At Associates you went into sleep science proper — the NREM/REM architecture, Borbély's two-process model, the ascending arousal system in survey, memory consolidation at hippocampal-cortical-dialogue level, chronobiology including the SCN, and the principal sleep disorders in survey. At Bachelor's you went circuit-deep, molecular-deep, and clinical-deep — the Saper-Scammell-Lu flip-flop framework, the BMAL1/CLOCK/PER/CRY transcription-translation feedback loop, sharp-wave ripples and the synaptic homeostasis hypothesis, OSA phenotyping at Eckert depth, the Schenck-Postuma RBD-to-α-synucleinopathy lineage, polysomnography at signal-detection depth, and the validity gap between consumer wearables and validated research instruments. At the end of Bachelor's you could read a primary sleep neuroscience paper and recognize what you were looking at.

This chapter is the third step of the upper-division spiral.

At the Master's level, Coach Sleep goes clinical and translational. The circuit and molecular neuroscience you learned at Bachelor's is the substrate of this chapter, not its content. What this chapter asks is the next question: given what we know about how sleep works, what does clinical sleep medicine actually do in practice, what circadian-medicine clinical applications have we translated, what does the population-scale picture of sleep look like, and where does sleep meet aging and neurodegeneration? This is the graduate question for sleep specifically. Sleep medicine is a relatively young clinical sub-specialty, still consolidating its identity at the intersection of neurology, pulmonology, psychiatry, dentistry, and primary care, and its translational landscape contains both substantial successes (the rise of CBT-I as first-line insomnia treatment, CPAP for OSA, light therapy for SAD) and substantial limits (the under-diagnosis of OSA, the over-prescription of sleep medications, the chronic-short-sleep epidemic). The graduate-level student becomes able to read this landscape as a working translational landscape rather than as a textbook synthesis.

The voice is the same Cat. Calm. Knows when to rest. Deeply efficient. Direct. What changes again is the depth. At Master's you are reading the primary clinical trials, the practice guidelines, the systematic reviews and meta-analyses, the failed translation programs and the successful ones, and the public-health data that constitutes the actual record of contemporary sleep medicine.

A word about what this chapter is not, before you begin. This chapter is not a clinical-prescribing manual. Insomnia, OSA, narcolepsy, RBD, restless legs syndrome, and the broader landscape of sleep disorders are real, well-researched, and present in these pages at clinical translational depth. They are not framed as conditions for you to diagnose in yourself or in others, and the chapter's treatment of CBT-I delivery, CPAP titration, sleep-medication prescribing, light-therapy protocols, and chronotherapy is descriptive of the research and clinical practice — never a personal prescription. The clinical work of sleep medicine is the work of trained sleep medicine physicians, behavioral sleep medicine specialists, registered polysomnographic technologists, dental sleep medicine providers, and the multidisciplinary teams within which they operate. The graduate-trained adjacent practitioner becomes able to read the literature and engage with clinical colleagues — never to substitute for clinical training.

A word about being a master's-level student in sleep-adjacent fields, before you begin. This audience reads the chapter from a different position than the Bachelor's audience did. Some of you are training to be clinical psychologists working in behavioral sleep medicine, licensed mental health counselors who will encounter insomnia in virtually every clinical caseload, public-health nutritionists or public mental-health professionals integrating sleep into population intervention, exercise physiologists for whom sleep is recovery, dental hygienists or dentists for whom OSA recognition is now part of the practice standard, or neurology and psychiatry trainees for whom sleep medicine is an adjacent sub-specialty. The chapter is written for that audience. The framing throughout remains recognition, clinical reasoning, and methodological depth — never diagnostic prescription. Clinical sleep medicine is its own discipline; you are training to be informedly adjacent to it, not to be it.

A word about sleep and mental health, before you begin. The bidirectional relationship between sleep disruption and mood disorders is one of the most robust findings in contemporary clinical neuroscience, and the relationship will appear in nearly every population a master's-trained practitioner will serve. The 2011 Baglioni meta-analysis established insomnia as a prospective predictor of major depressive disorder; subsequent work has extended the framework across mood and anxiety disorders, suicidal ideation, substance use, and adolescent mental health. The graduate-trained practitioner recognizes sleep disruption as a clinical signal — not as a casual lifestyle complaint — and engages with it accordingly. If anything in this chapter — about chronic insomnia, about the sleep-and-suicide literature, about the conditions that disrupt sleep across the lifespan — touches your own experience and you are working through it alone when you do not need to be, the verified crisis resources at the end of this chapter are real. Your program's counseling resources are real. The Cat is patient with you.

This chapter has five lessons.

Lesson 1 is Clinical Sleep Medicine and the Treatment Landscape — the Spielman 3P (predisposing, precipitating, perpetuating) model as foundational anchor and as the clinical framework that underwrites contemporary insomnia practice, CBT-I as first-line insomnia treatment at intervention-trial depth (Morin, Edinger, Carney), sleep medications at receptor pharmacology depth (Z-drugs at GABA-A binding selectivity, suvorexant and the dual orexin receptor antagonist class, ramelteon at melatonin-receptor depth, trazodone off-label use and its limited evidence base, benzodiazepines and the long-term use problem), OSA treatment at clinical depth (CPAP adherence as the central practical problem, the Eckert phenotyping-based treatment approach, mandibular advancement devices, hypoglossal nerve stimulation, weight loss in obesity-related OSA), narcolepsy treatment at clinical pharmacology depth (modafinil, sodium oxybate, the orexin agonist research direction), and the benzodiazepine-opioid co-prescribing risk at FDA-black-box-warning depth.

Lesson 2 is Circadian Medicine Clinical Applications — shift work disorder treatment, jet lag protocols at intervention-trial depth (Eastman, Burgess work on light-timing protocols), melatonin agonists at receptor pharmacology depth (ramelteon for sleep onset, tasimelteon for non-24-hour sleep-wake disorder in totally blind individuals), light therapy for seasonal affective disorder at clinical implementation depth (Rosenthal lineage at clinical translational depth), delayed sleep phase disorder and chronotherapy in adolescents, and the molecular clock as drug target descriptively (currently no clinical interventions but active research).

Lesson 3 is Sleep Epidemiology and the Public Health of Sleep — the chronic short sleep epidemic at population data depth (CDC sleep duration trends), shift work as occupational health issue (the IARC 2007/2019 Group 2A classification at translational/policy depth), pediatric sleep and the school-start-time research (Wahlstrom, the AAP 2014 recommendation, real-world implementation studies), the sleep-and-mental-health bidirectional relationship at epidemiological depth (Baglioni 2011 systematic review), drowsy driving as life-safety public health issue (AAA Foundation data).

Lesson 4 is Sleep, Aging, and Neurodegenerative Disease — sleep architecture changes across the lifespan, the glymphatic clearance hypothesis and Alzheimer's at translational research depth (Nedergaard and Iliff foundational work, Lucey 2022 slow-wave activity in preclinical AD), the Aβ-sleep bidirectional relationship (David Holtzman work on Aβ clearance during sleep), REM behavior disorder as α-synucleinopathy prodrome at clinical practice depth (Postuma's longitudinal cohort work showing high conversion rates within 14 years), the sleep-and-cognitive-decline observational research and its causal inference limits, and the IARC night shift classification revisited at oncology translational depth. Direct lateral to Coach Brain Master's Lesson 4 on the inflammatory hypothesis — sleep-inflammation-mood-cognition is the integrated translational territory.

Lesson 5 is Sleep Research Methods at Translational Depth — the polysomnography versus actigraphy versus consumer wearable hierarchy at clinical practice depth (de Zambotti 2019 validity gap paper at Master's translational depth — what wearables can and cannot tell us clinically), the sleep deprivation paradigm limits (total versus chronic partial), the five-point evaluation framework applied to sleep claims specifically (the "athletes need 10 hours" claim, polyphasic sleep claims, sleep tracker accuracy claims, the magnesium-for-sleep supplement research versus marketing), and the publication-bias picture in sleep medicine trials.

The Cat is in no hurry. Begin.

---

Lesson 1: Clinical Sleep Medicine and the Treatment Landscape

Learning Objectives

By the end of this lesson, you will be able to:

• Describe the Spielman 3P (predisposing, precipitating, perpetuating) model of insomnia and articulate why it has organized clinical insomnia practice for nearly four decades
• Describe Cognitive Behavioral Therapy for Insomnia (CBT-I) at intervention-trial depth, identify the principal components (sleep restriction, stimulus control, cognitive therapy, sleep hygiene, relaxation), and articulate the magnitude of effect in published trials
• Describe the principal sleep-medication classes — Z-drugs, dual orexin receptor antagonists, melatonin agonists, trazodone off-label, benzodiazepines — at receptor pharmacology depth, and identify the evidence base, indications, and limits of each
• Describe contemporary OSA treatment at clinical depth, including the CPAP adherence problem and the Eckert phenotyping-based treatment approach
• Articulate the benzodiazepine-opioid co-prescribing risk at FDA-black-box-warning depth and identify the clinical-population contexts in which the risk is most acute

Key Terms

Why the Treatment Landscape Anchors This Chapter

A graduate-level chapter on clinical sleep medicine does not begin with the most-discussed sleep-tracking technology of the moment. It begins with the treatments we actually have, the frameworks within which they are delivered, and the gap between the research promise of each treatment and its real-world clinical effect. The contemporary sleep-medicine treatment landscape is a substantial translational story: behavioral interventions with multi-decade evidence bases, pharmacological options that have improved meaningfully in the past decade with the arrival of the dual orexin receptor antagonist class, and the persistent gap between what we know works and what is actually delivered in practice. The graduate-trained adjacent practitioner reads this landscape because it is the operational reality within which sleep disturbance is addressed, and because it is the cleanest available case study of what sleep medicine does and does not yet achieve.

The Spielman 3P Model: Foundational Anchor

In 1986, Arthur Spielman, Paul Caruso, and Paul Glovinsky published in Sleep Medicine Clinics a foundational paper, A behavioral perspective on insomnia treatment, articulating what has come to be called the 3P model: a framework distinguishing the predisposing, precipitating, and perpetuating factors of chronic insomnia [1]. The paper is the foundational anchor for this chapter and remains the most-cited conceptual framework in clinical insomnia practice nearly four decades later.

The model's structure: every individual carries some level of predisposing vulnerability to insomnia — trait-level features including baseline arousal level, cognitive style, biological clock characteristics, and personal history. The predisposing vulnerability is typically not sufficient to produce clinical insomnia in itself. When a precipitating event occurs — an acute stressor, a medical event, a life transition, an environmental disruption — the vulnerable individual develops acute insomnia. The acute insomnia would, in many cases, resolve spontaneously as the precipitant resolves. What converts acute insomnia into chronic insomnia is perpetuating factors: behavioral and cognitive responses to the acute insomnia that, while intuitively reasonable, actually maintain the disturbance after the precipitant has faded. The principal perpetuating factors are extension of time in bed (compensating for poor sleep by staying in bed longer, which reduces sleep efficiency and weakens the bed–sleep association), daytime napping (further reducing nighttime sleep drive), variable wake time (uncoupling the circadian system from sleep), and the cognitive-arousal pattern of worry and anticipation around sleep that itself produces hyperarousal at bedtime.

The clinical implication of the model is structural and decisive. Chronic insomnia is maintained by the perpetuating factors more than by the original precipitant. The original precipitant, even when identifiable, is rarely directly treatable. The perpetuating factors are behaviorally modifiable. The model directs treatment toward the perpetuating factors — and that direction is the conceptual basis of contemporary CBT-I.

The model has held up across nearly four decades of empirical and clinical work. Refinements (the addition of attention-bias and rumination components, the integration with hyperarousal models from Bonnet and Arand, the development of stimulus-control specifically targeting the bed–sleep association weakening) extend the framework without replacing it [2][3]. The graduate-trained practitioner reads any clinical insomnia paper through this framework; the framework's vocabulary has become the operating language of behavioral sleep medicine.

CBT-I as First-Line Insomnia Treatment

The translation of the Spielman framework into a manualized, replicable, RCT-tested clinical intervention is the achievement of Cognitive Behavioral Therapy for Insomnia. CBT-I is a multi-component behavioral intervention typically delivered in 4–8 sessions (4–6 sessions is typical for current protocols; abbreviated 1–2 session protocols have been tested with promising results) [4]. The principal components:

Sleep Restriction Therapy (SRT). The intervention limits time in bed to the patient's average reported sleep duration (with a floor of approximately 5–5.5 hours to avoid excessive daytime impairment). The compressed sleep window initially produces increased sleep drive and improved sleep efficiency. As sleep efficiency rises above approximately 85–90% over consecutive nights, time in bed is gradually extended in 15-minute increments. The net effect is reconsolidation of sleep into a defined window with high efficiency and the rebuilding of normal sleep architecture [5][6].

Stimulus Control. Bootzin's stimulus-control framework (1972, formalized into CBT-I subsequently) re-establishes the bed–sleep association by behavioral instructions: use the bed only for sleep and intimacy, leave the bed when awake for more than approximately 15 minutes and return only when sleepy, maintain consistent wake time independent of nighttime sleep quality, and eliminate daytime napping [7]. The framework directly targets the perpetuating factor of weakened bed–sleep association.

Cognitive Therapy. Identification and modification of the catastrophic, worry-laden, performance-anxious cognitive pattern around sleep — including the typical patient beliefs that "I must get 8 hours," "If I don't sleep tonight I won't function tomorrow," and "Other people sleep effortlessly and I cannot." The cognitive component uses standard CBT techniques (thought-record identification, evidence-based examination, behavioral experiments) targeted at sleep-specific cognitions [8].

Sleep Hygiene Education. The component that lay audiences typically identify with "sleep hygiene" — recommendations regarding caffeine, alcohol, the sleep environment, exercise timing, and meal timing. Hygiene alone is the weakest component of CBT-I and is insufficient as standalone treatment; it serves as a component of the broader intervention rather than a complete approach [9].

Relaxation Training. Progressive muscle relaxation, autogenic training, and related techniques addressing pre-sleep arousal. The component is helpful as adjunct; like sleep hygiene it is insufficient as standalone treatment [10].

The intervention-trial evidence base for CBT-I is among the strongest in behavioral medicine. The landmark Morin et al. 1999 JAMA RCT randomized older adults with chronic primary insomnia to CBT-I, temazepam, combined, or placebo, demonstrating CBT-I superiority over medication in the long-term maintenance of treatment gains [11]. Subsequent RCTs have replicated efficacy across primary insomnia and comorbid insomnia (insomnia in the context of medical and psychiatric conditions), across delivery formats (individual, group, telehealth, digital/internet-delivered), and across patient populations including older adults, perinatal women, cancer patients, and those with chronic pain [12][13][14][15]. The Trauer et al. 2015 Annals of Internal Medicine meta-analysis of CBT-I in chronic insomnia found large effect sizes on sleep onset latency (improvement of approximately 19 minutes), wake after sleep onset (improvement of approximately 26 minutes), and sleep efficiency (improvement of approximately 10%), with effects maintained at 6–12 month follow-up [16].

The contemporary clinical guidance is uniform across major sleep medicine professional societies. The American Academy of Sleep Medicine clinical practice guideline (Edinger et al. 2021) recommends CBT-I as the first-line treatment for chronic insomnia disorder in adults [17]. The American College of Physicians clinical practice guideline (Qaseem et al. 2016) makes the same recommendation [18]. The European Sleep Research Society guideline (Riemann et al. 2017) and the Veterans Health Administration / Department of Defense guideline make the same recommendation [19]. Across guidelines, pharmacotherapy is positioned as second-line, used for the duration required for the patient to engage with behavioral treatment, or in patients for whom CBT-I is unavailable or unsuccessful.

The principal real-world barrier is access. CBT-I-trained clinicians are concentrated in academic medical centers, urban areas, and specialty sleep clinics; rural and many community-practice areas have limited access to in-person CBT-I. The contemporary expansion of digital CBT-I (Sleepio and related platforms, with substantial RCT evidence) and telehealth-delivered CBT-I has improved access but has not fully closed the gap [20][21]. The graduate-level practitioner in clinical psychology, behavioral medicine, or adjacent fields who can deliver or refer competently to CBT-I addresses a real and persistent unmet need.

Z-Drugs and the GABA-A Pharmacology of Sleep

The Z-drugs — zolpidem, zaleplon, eszopiclone — are non-benzodiazepine GABA-A receptor positive allosteric modulators with relative selectivity for the α1-containing GABA-A receptor subtype that mediates sedation [22]. The selectivity is partial rather than absolute; at clinical doses Z-drugs bind α2 and α3 subtypes as well, with the receptor occupancy responsible for the side-effect profile (anxiolysis, muscle relaxation, anterograde amnesia, and the complex sleep-related behaviors — sleep-eating, sleep-walking, sleep-driving — that produced FDA dose-reduction recommendations for zolpidem in 2013, particularly for women) [23].

The clinical pharmacology of the Z-drugs differs by half-life. Zaleplon's very short half-life (~1 hour) makes it appropriate for sleep-onset difficulty without daytime carryover; zolpidem's intermediate half-life (~2.5 hours, with the controlled-release formulation extending the effect for sleep maintenance) addresses both sleep onset and middle-of-night awakening in some patients; eszopiclone's longer half-life (~6 hours) addresses sleep maintenance most directly but with greater morning sedation [24].

The efficacy of Z-drugs in chronic insomnia is moderate. The Cipriani-style network meta-analysis applied to insomnia pharmacotherapy (De Crescenzo et al. 2022 Lancet) reported moderate effect sizes for the Z-drugs on sleep onset latency and total sleep time relative to placebo, with magnitudes broadly comparable across the class [25]. The clinical effect is real and meaningful for short-term use; the question is the longer-term picture.

The long-term use problem with Z-drugs follows the contour of the benzodiazepine pattern from prior sleep medicine eras. Tolerance can develop over weeks of nightly use; dependence can develop with chronic use; rebound insomnia commonly emerges upon discontinuation after sustained use; the FDA in 2019 added boxed warnings about complex sleep behaviors and rare-but-serious injuries. The 2017 AASM guideline (Sateia et al.) and subsequent updates have positioned Z-drugs for short-term use as adjunct to behavioral treatment rather than as long-term monotherapy for chronic insomnia [26]. The clinical practice has not fully aligned with the guidance; Z-drug long-term prescription remains common, particularly in primary-care contexts where CBT-I access is limited.

Dual Orexin Receptor Antagonists: The Mechanistically Novel Class

The dual orexin receptor antagonist (DORA) class — suvorexant (Belsomra, FDA-approved 2014), lemborexant (Dayvigo, FDA-approved 2019), and daridorexant (Quviviq, FDA-approved 2022) — is the most mechanistically significant pharmacological development in clinical sleep medicine since the introduction of the benzodiazepines. Unlike the Z-drugs and benzodiazepines, which promote sleep by enhancing GABA-mediated inhibition, the DORAs promote sleep by reducing wake-promoting orexin signaling — antagonizing the orexin receptors at which orexin (hypocretin) neurons of the lateral hypothalamus produce arousal [27].

The mechanistic logic is direct: the lateral hypothalamic orexin system is the principal stabilizer of wakefulness (the Saper-Scammell-Lu framework from Sleep Bachelor's Lesson 1), and pharmacological antagonism of the system shifts the flip-flop balance toward sleep without enhancing the broader inhibitory tone that produces the cognitive, motor, and complex-behavior side effects of GABA-A enhancement. The clinical effect is sleep promotion with relatively preserved sleep architecture (less suppression of REM than benzodiazepines produce) and a side-effect profile that includes morning somnolence, abnormal dreams, and a small risk of sleep paralysis [28].

The efficacy evidence for the DORAs in chronic insomnia is moderate. The pivotal RCTs (Herring et al. 2016 Biological Psychiatry for suvorexant; Yardley et al. 2021 Sleep for lemborexant; Mignot et al. 2022 Lancet Neurology for daridorexant) demonstrated improvement in sleep onset latency, wake after sleep onset, and total sleep time relative to placebo, with effect sizes in the moderate range comparable to the Z-drug class [29][30][31]. The principal clinical advantages over the Z-drug class are the mechanistic novelty (which translates to reduced tolerance development in available evidence, though longer follow-up is needed), the absence of complex sleep behaviors at meaningful frequency, and the absence of the controlled-substance scheduling of the benzodiazepines (suvorexant is Schedule IV; the more recent DORAs have similar scheduling). The principal disadvantages are cost (substantial out-of-pocket cost in many insurance contexts), morning carryover sedation in some patients, and the more conservative net-clinical-effect magnitude on measures like sleep onset latency relative to Z-drugs.

The clinical role of the DORA class in contemporary practice is expanding as cost barriers diminish and as evidence accumulates. The class represents the strongest available pharmacological option when behavioral treatment is contraindicated, unavailable, or unsuccessful; the mechanistic distinction from GABA-A modulation makes the class particularly appropriate for patients with histories of benzodiazepine or Z-drug dependence or in whom GABA-A enhancement is problematic for other reasons.

Trazodone: Off-Label Use and Its Limited Evidence Base

Trazodone is FDA-approved at antidepressant doses (150–600 mg) for major depressive disorder. At sub-antidepressant doses (25–100 mg at bedtime), trazodone is among the most-prescribed sleep agents in the United States — and one of the most controversial in the sleep medicine literature [32].

The mechanistic basis for trazodone's sedating effect is principally 5-HT2A antagonism with adjunct H1 and α1-adrenergic antagonism at low doses [33]. The clinical effect on sleep is real; the question is the evidence base for the off-label use, which is substantially thinner than the prescription pattern would suggest.

The 2017 AASM clinical practice guideline explicitly recommended against trazodone for sleep-onset or sleep-maintenance insomnia in adults, on the basis of weak evidence for efficacy at the doses typically used and meaningful side-effect concerns (morning sedation, orthostatic hypotension particularly in older adults, priapism rarely) [26]. Despite the guideline, trazodone prescription for sleep has continued at high volume, particularly in primary care, in geriatrics, and in patients with concerns about controlled-substance prescribing of Z-drugs.

A graduate-level reading of the trazodone-for-sleep literature recognizes the tension. The clinical effect is real for many patients; the cost is low; the controlled-substance concerns of Z-drugs are absent; the long-term-use research base is thinner than the prescription pattern requires; the guideline-level recommendation is against use. The translational landscape illustrates the gap between guideline-level recommendation and real-world practice that characterizes much of contemporary sleep medicine.

Benzodiazepines: The Legacy Class and the Long-Term Use Problem

Benzodiazepines (temazepam, triazolam, estazolam, lorazepam, clonazepam at off-label use) were the principal pharmacological sleep aid from the 1960s through the 1980s. They produce sleep through GABA-A receptor positive allosteric modulation without the relative subtype selectivity of the Z-drugs, resulting in broader effects on cognition, motor function, and other receptor systems [34].

The clinical use of benzodiazepines specifically for chronic insomnia has declined substantially with the arrival of the Z-drugs, the DORAs, and the broader recognition of the long-term use problem treated at depth in Coach Brain Master's Lesson 1 — tolerance development, physiological dependence with protracted withdrawal syndromes, cognitive impairment with chronic use, falls and fractures in older adults, and elevated mortality particularly in combination with opioids [35][36]. The contemporary clinical guidance uniformly recommends against long-term benzodiazepine monotherapy for chronic insomnia; the deprescribing literature has expanded substantially as the long-term use problem has been recognized at clinical scale.

The Benzodiazepine-Opioid Co-Prescribing Risk

A specific and life-safety-relevant surface deserves explicit Master's-level attention: the co-prescribing of benzodiazepines and opioids. The FDA issued boxed warnings in 2016 on benzodiazepine and opioid co-prescription, reflecting accumulating evidence that the combination produces respiratory depression at meaningfully increased rates compared to either class alone, with substantial mortality consequences [37].

The mechanism is direct. Benzodiazepines enhance GABAergic inhibition at GABA-A receptors throughout the CNS including respiratory control centers in the brainstem. Opioids inhibit respiratory drive principally at the pre-Bötzinger complex (the respiratory rhythm generator) and the parabrachial-Kölliker-Fuse complex (the chemoreceptor-mediated inspiratory drive), through μ-opioid receptor-mediated effects on neuronal excitability and synaptic transmission. The combined inhibition produces hypoventilation, hypercapnia, hypoxemia, and in severe cases respiratory arrest. The pharmacological interaction is super-additive at clinically relevant doses, not merely additive — the combination produces greater respiratory depression than the algebraic sum of the individual effects predicts [38].

This material connects directly to Breath Bachelor's Lesson 1 on respiratory neural control and opioid-induced respiratory depression. The Master's-level practitioner working in clinical psychology, behavioral medicine, public mental health, addiction services, or adjacent fields will encounter patients on chronic opioid therapy (for chronic pain, in opioid-use-disorder treatment, in palliative care) who are also being considered for or are already receiving benzodiazepines. The clinical management of this co-prescription is the work of the prescribing clinician(s); the graduate-level adjacent practitioner who recognizes the risk and can engage informedly with the clinical team about it operates within scope and contributes meaningfully to safe care.

The Sun et al. 2017 BMJ retrospective analysis of Medicare data demonstrated the magnitude: concurrent benzodiazepine and opioid prescribing was associated with significantly elevated overdose risk compared to opioid prescribing alone, with the effect size increasing with duration of overlap and benzodiazepine dose [39]. The CDC opioid prescribing guideline (2016 and subsequent updates) explicitly addressed the co-prescribing risk and recommended avoidance of concurrent prescription whenever possible [40]. The clinical implementation of these guidelines has been substantial but uneven; the co-prescription pattern persists in many contexts, and the graduate-trained adjacent practitioner has a real role in supporting safer practice.

OSA Treatment at Clinical Depth

OSA is one of the most under-diagnosed common conditions in clinical medicine, with an estimated 80% of moderate-to-severe OSA in U.S. adults remaining undiagnosed at population-prevalence estimates [41]. The treatment landscape has been dominated for four decades by continuous positive airway pressure (CPAP) — the first-line treatment, developed by Colin Sullivan and colleagues in 1981 [42], and the principal definitive intervention for moderate-to-severe OSA.

The central practical problem of CPAP is adherence. Despite the treatment's well-established efficacy on the polysomnographic Apnea-Hypopnea Index (AHI), daytime sleepiness, and cardiovascular biomarkers, observational and registry data consistently show that approximately 50% of patients prescribed CPAP discontinue use within the first year, and many of those who continue use it for inadequate duration (the conventional clinical threshold is ≥4 hours per night on ≥70% of nights) [43][44]. The adherence problem is multifactorial — mask comfort, claustrophobia, partner-bed-sharing effects, dryness, noise, the psychological burden of nightly device use, the variable congruence between subjective sleep improvement and objective efficacy — and substantial clinical effort goes into supporting adherence through mask fitting, pressure adjustment, humidification, behavioral support, and patient education.

The Eckert phenotyping framework — introduced at Bachelor's depth from his 2013 American Journal of Respiratory and Critical Care Medicine work [45] — provides a framework for matching treatment to the dominant pathophysiological mechanism in the individual patient. The four endotypes are:

• Pcrit (collapsibility): airway anatomical vulnerability. Treatment matches include CPAP, MAD, upper airway surgery, weight loss in obesity-related OSA.
• Loop gain (ventilatory control instability): treatment matches include supplemental oxygen, acetazolamide, and emerging interventions.
• Arousal threshold: low arousal threshold contributes to OSA by terminating respiratory events early before stabilizing recovery. Treatment matches include sedatives that raise arousal threshold without further suppressing respiratory drive (a delicate clinical-pharmacology balance).
• Muscle responsiveness (upper-airway dilator muscle reflex activity during sleep): treatment matches include hypoglossal nerve stimulation, dronabinol and other pharmacological approaches under investigation.

The clinical translation of the phenotyping framework has been gradual. Routine phenotype assessment is not standard in community sleep medicine; specialized academic sleep centers offer phenotyping with subsequent personalized treatment selection. The 2019 Eckert and Wellman review and subsequent work have continued to develop the framework toward broader clinical adoption [46].

Mandibular advancement devices (MAD) are first-line for mild-to-moderate OSA when CPAP is not tolerated and in selected patients with positional OSA. The treatment is delivered by dental sleep medicine providers; the clinical efficacy is well-established in selected patients though typically less complete than CPAP on AHI reduction; the adherence advantage over CPAP is substantial in many patients [47].

Hypoglossal nerve stimulation (HGNS) is FDA-approved (Inspire, 2014) for moderate-to-severe OSA in patients who cannot tolerate CPAP, with specific eligibility criteria including AHI range, BMI, and absence of complete concentric retropalatal collapse on drug-induced sleep endoscopy [48]. The clinical role has expanded as the device evidence base has accumulated; outcomes in appropriately selected patients are substantial.

Weight loss in obesity-related OSA produces meaningful AHI improvement in most patients, with severity reduction proportional to weight loss magnitude. The Foster et al. 2009 Archives of Internal Medicine RCT in obese diabetic patients with OSA demonstrated significant AHI reduction with intensive lifestyle intervention compared to diabetes-education control [49]. Bariatric surgery in severe obesity produces substantial AHI improvement and sometimes resolution of moderate OSA. The clinical translation requires recognition that weight loss is an adjunct to airway treatment rather than a replacement; OSA may persist after substantial weight loss, and CPAP or alternative airway treatment remains indicated until polysomnographic resolution is documented.

Narcolepsy Treatment

Narcolepsy treatment has evolved substantially with the recognition of orexin (hypocretin) deficiency as the pathophysiological basis of type 1 narcolepsy (from Mignot's foundational work, treated at Bachelor's depth).

Modafinil and armodafinil (the R-enantiomer) are wake-promoting agents widely used as first-line treatment for excessive daytime sleepiness in narcolepsy and as adjunct in OSA-related residual sleepiness. The mechanism involves dopamine transporter inhibition with broader monoaminergic effects; the side-effect profile is generally favorable with the principal concern being interaction with hormonal contraceptives [50].

Sodium oxybate (Xyrem) and the lower-sodium formulation (Xywav) are FDA-approved for narcolepsy with cataplexy. The drug is administered at bedtime and again 2.5–4 hours later, with substantial effect on cataplexy frequency and on daytime sleepiness. The mechanism is principally GABA-B receptor agonism with effects on slow-wave sleep enhancement that may underlie clinical efficacy [51]. The clinical use requires close oversight given the drug's narrow therapeutic index, the requirement for restricted distribution (REMS program), and the abuse potential.

Pitolisant is an H3 receptor inverse agonist FDA-approved for excessive daytime sleepiness in narcolepsy, providing a mechanistically novel option that does not carry abuse potential [52].

Solriamfetol is a dopamine and norepinephrine reuptake inhibitor FDA-approved for excessive daytime sleepiness in narcolepsy and OSA [53].

The orexin agonist research direction is among the most-anticipated developments in narcolepsy treatment. With type 1 narcolepsy mechanistically grounded in orexin deficiency, direct replacement via orexin receptor agonists has been a long-pursued translational target. The first-in-class orexin-2 receptor agonist clinical trials (TAK-861 and others in development) have reported meaningful effects in initial Phase 2 work; the class is at active development stage as of mid-2026 [54].

What This Lesson Built

The treatment landscape this lesson surveyed is the operational reality of clinical sleep medicine. The master's-level student should leave able to read a clinical sleep trial in this space with attention to design, comparator, effect size, the guideline-versus-practice gap, and the specific clinical-translation challenges of the modality. The student should be able to articulate CBT-I as first-line for chronic insomnia at intervention-trial depth, the DORA class as the mechanistically novel addition since benzodiazepines, the CPAP adherence problem as the central practical limit of contemporary OSA treatment, the benzodiazepine-opioid co-prescribing risk at FDA-warning depth, and the Spielman 3P framework as the conceptual backbone of behavioral sleep medicine.

This lesson is not a clinical-prescribing manual. It is a description of the field's current state. The actual prescribing of sleep medications, the delivery of CBT-I, the titration of CPAP, the dental fitting of MAD devices, the surgical placement of HGNS, and the clinical management of narcolepsy are the work of trained clinicians within established clinical relationships.

Lesson Check

1. Describe the Spielman 3P model and articulate why the perpetuating factor framework drives contemporary CBT-I treatment design.
2. List the five principal components of CBT-I and identify which is the strongest and which is the weakest standalone component.
3. Compare Z-drugs and dual orexin receptor antagonists at the level of: receptor mechanism, principal clinical effect, side-effect profile, and abuse/dependence risk.
4. Articulate the benzodiazepine-opioid co-prescribing risk at FDA-warning depth. What is the pharmacological mechanism, and what is the clinical population context in which the risk is most acute?
5. Apply the Eckert phenotyping framework to OSA treatment selection. For each endotype (Pcrit, loop gain, arousal threshold, muscle responsiveness), identify one treatment option matched to that mechanism.

---

Lesson 2: Circadian Medicine Clinical Applications

Learning Objectives

By the end of this lesson, you will be able to:

• Describe shift work disorder at clinical definition depth, identify the principal interventions tested in the shift-work population (phase-advanced light, modafinil/armodafinil, melatonin, scheduling design), and articulate the magnitude of effect and limits of each
• Apply the Eastman and Burgess light-timing protocols for jet lag to a clinical case, identifying the appropriate direction of phase shift, timing of light exposure and avoidance, and adjunctive melatonin timing
• Describe the melatonin receptor agonist class (ramelteon, tasimelteon) at receptor pharmacology depth and identify the specific indications for tasimelteon in non-24-hour sleep-wake disorder
• Articulate the clinical implementation of bright light therapy for seasonal affective disorder at the level of intensity (lux), duration, timing, and clinical context, and describe the evidence-base development from Rosenthal through subsequent meta-analyses
• Describe delayed sleep phase disorder and chronotherapy in adolescents at clinical practice depth, identifying the principal interventions (light timing, melatonin timing, scheduled sleep advancement) and the practical limits of each

Key Terms

Why Circadian Medicine at Master's

Circadian medicine is among the more successful translational stories in sleep medicine, with two FDA-approved melatonin receptor agonists, a substantial light-therapy evidence base for SAD, defined clinical protocols for jet lag and shift work, and emerging clinical-translational applications for cancer chronotherapy and cardiovascular event timing. The graduate-level engagement with this material requires the depth to translate the Bachelor's-tier phase-response-curve framework (from Sleep Bachelor's Lesson 2 and Light Bachelor's Lesson 3) into clinical decisions, and the methodological honesty to identify where circadian-medicine claims outrun their evidence.

This lesson connects laterally to Coach Light Bachelor's Lesson 3 on the PRC clinical applications — the Bachelor's tier covered the PRC at mechanism depth; this lesson applies the PRC at clinical-practice depth. The two lessons should be read in conjunction.

Shift Work Disorder

Shift work disorder is a circadian rhythm sleep-wake disorder defined in the International Classification of Sleep Disorders (ICSD-3) as recurrent symptoms of insomnia, excessive sleepiness, or both, in association with a work schedule that requires activity during the biological night and rest during the biological day [55]. The disorder affects a substantial subset of shift workers; prevalence estimates among shift workers vary by definition and population from approximately 10% to 30% [56].

The principal interventions tested in shift work disorder have been:

Phase-advanced light protocols. Eastman and colleagues have demonstrated that strategically-timed bright light during the night shift, combined with daytime light avoidance during the morning commute and post-shift sleep, can produce partial phase shifts of the circadian system toward better alignment with the work schedule [57][58]. The protocols achieve partial adaptation in most workers; complete adaptation is rare given the inevitable daytime light exposure and the social demands of weekend life that re-establish daytime biological rhythms. The Eastman protocols have substantial evidence at intervention-research depth and represent the most-developed non-pharmacological approach to shift work disorder.

Modafinil and armodafinil are FDA-approved for excessive sleepiness in shift work disorder. The clinical effect on subjective and objective alertness during the night shift is meaningful; the effect on post-shift daytime sleep is generally minimal [59]. The medications address the wakefulness side of the schedule mismatch without addressing the underlying circadian misalignment.

Melatonin at appropriate dose and timing can promote post-shift daytime sleep onset and consolidation. The clinical evidence is moderate; the magnitude of effect on objective sleep parameters is small-to-moderate, with the more substantial effect on subjective sleep quality and pre-sleep difficulty falling asleep [60].

Scheduling design — including the direction of rotation (forward versus backward), the speed of rotation, and the inclusion of permanent night-shift assignments versus rotating shifts — affects shift-work tolerance independent of individual-level intervention. The contemporary consensus favors forward-rotating schedules (morning → evening → night) with extended rotation periods over backward-rotating or rapidly-rotating schedules; the occupational-health literature has accumulated substantial evidence on schedule design [61].

The public health framing of shift work itself — the IARC 2007/2019 Group 2A classification of night shift work as probably carcinogenic to humans, with breast and prostate cancer as the principal sites of concern — was treated at Bachelor's depth in Coach Light Bachelor's. At Master's translational/policy depth (lateral to Lesson 3 of this chapter), the question of how to operationalize the IARC classification into actionable occupational health policy is unresolved. The translation has produced increased research investment, some changes in workplace policy in selected jurisdictions, and modest changes in employer practices around schedule design, but it has not produced the structural workplace reform that an unambiguous carcinogen classification typically catalyzes [62][63].

Jet Lag and the Eastman-Burgess Light-Timing Protocols

Jet lag is the transient circadian misalignment produced by rapid trans-meridian travel. The clinical management is one of the cleaner applied chronobiology stories: the principles are well-understood (the PRC, light as the principal zeitgeber, melatonin as adjunctive), the protocols are well-developed (the Eastman/Burgess light-timing-and-melatonin protocols), and the magnitude of clinical effect is meaningful for travelers willing to engage with the protocols.

The Eastman and Burgess framework integrates direction of travel, time-zone shift magnitude, and pre-trip preparation into operational protocols [64][65]. The principles:

• For eastward travel (which requires advancing the circadian phase): the body needs to shift earlier. Morning bright light advances the phase; evening light delays it. The protocol uses scheduled morning light exposure starting before the trip (advancing the home phase in preparation) and continuing at the destination, with evening light avoidance during the same window. Adjunctive low-dose melatonin (0.5–3 mg) in the late afternoon to early evening (a melatonin-PRC phase-advance window) supports the shift.

• For westward travel (which requires delaying the circadian phase): the body needs to shift later. Evening bright light delays the phase; morning light advances it. The protocol uses scheduled evening light exposure at the destination with morning light avoidance, supplemented by melatonin in the early morning (a melatonin-PRC phase-delay window). Westward jet lag is generally easier to manage than eastward because the human circadian period averages slightly longer than 24 hours, biasing the system toward delays.

• For larger time-zone shifts (>6 hours), partial pre-trip phase shifting can substantially reduce the destination-side adjustment. The Eastman protocols include specific pre-trip schedules for shifts up to 9 hours [65].

The clinical implementation of these protocols is the work of travel medicine, sleep medicine, and motivated individual travelers. The published evidence base is substantial; the principal practical limit is patient adherence to the daily-life-disrupting pre-trip schedule changes. The Burgess 2003 Journal of Biological Rhythms paper formalized many of the principles [66]; subsequent work has refined the protocols and extended them to specific populations (athletes traveling for competition, business travelers, military personnel) [67].

Melatonin Receptor Agonists: Ramelteon and Tasimelteon

The melatonin signaling pathway operates through two G-protein-coupled receptors, MT1 and MT2, both of which couple to Gαi/o pathways producing inhibitory cellular effects. MT1 receptors are expressed in the SCN and contribute to the acute sleep-promoting effect of melatonin; MT2 receptors are expressed in the SCN, retina, and other sites and mediate the phase-shifting effect [68].

Ramelteon (Rozerem, FDA-approved 2005) is a selective MT1/MT2 receptor agonist with approximately 6-fold higher affinity than melatonin for the receptors [69]. The clinical indication is sleep-onset insomnia; the drug is administered 30 minutes before bedtime; the effect on sleep onset latency is modest (improvement of approximately 7–10 minutes versus placebo in clinical trials) [70]. The clinical use has been moderate; the modest effect size and the availability of inexpensive over-the-counter melatonin (despite the very different pharmacokinetic profile) have limited adoption.

Tasimelteon (Hetlioz, FDA-approved 2014) is a selective MT1/MT2 receptor agonist FDA-approved for non-24-hour sleep-wake disorder — a circadian rhythm disorder occurring principally in totally blind individuals without functional retinal photoreception. In these patients, the absence of light input to the SCN means that the endogenous circadian system runs at its natural period (slightly longer than 24 hours) without entrainment to the 24-hour day. The resulting free-running circadian rhythm produces a pattern of progressively-delaying sleep onset and wake times across days, with periods of severe insomnia and daytime sleepiness as the circadian rhythm drifts in and out of alignment with the desired sleep schedule [71].

The clinical translation of tasimelteon for this population was a meaningful translational success: a defined patient population with an identifiable mechanism, a drug targeted at that mechanism, and clinical trials demonstrating entrainment in approximately 20% of treated patients with clinically meaningful improvements in nighttime sleep duration and daytime alertness [72]. The drug is administered nightly at the same target sleep time, providing a consistent phase-shifting signal that substitutes for the absent light input. The effect requires sustained nightly use and may take weeks to months to entrain; discontinuation produces re-emergence of the free-running pattern.

Tasimelteon has subsequently been approved for Smith-Magenis syndrome-associated sleep disturbance (a rare genetic condition with severe circadian dysregulation) [73] and is under investigation for additional circadian rhythm disorders. The drug illustrates the precision-medicine logic of circadian pharmacology at its strongest: defined patient population, mechanistically-grounded intervention, clinical-translation evidence.

The broader melatonin OTC landscape is sharply different from the prescription melatonin receptor agonist landscape. Over-the-counter melatonin (in doses from 0.3 mg to 10 mg) is widely available and widely used; the published evidence base for OTC melatonin in sleep-onset insomnia in healthy adults supports modest effect sizes on sleep onset latency [74]. The quality control of OTC melatonin products has been documented as variable; the Erland and Saxena 2017 Journal of Clinical Sleep Medicine analysis found substantial inter-product variability in actual melatonin content versus labeled content, with some products containing serotonin contamination [75]. The graduate-level clinician engages with patient OTC melatonin use with attention to dose, timing, formulation, and the product-quality question.

Light Therapy for Seasonal Affective Disorder

The clinical use of bright light for seasonal affective disorder (SAD) traces to the foundational work of Norman Rosenthal and colleagues at NIMH in the 1980s, with the seminal 1984 Archives of General Psychiatry paper formally describing the syndrome and demonstrating bright light response [76]. The clinical translation has accumulated substantial evidence over the subsequent four decades.

The standard clinical protocol uses 10,000 lux of broad-spectrum white light or 2,500 lux of broad-spectrum white light delivered at a closer distance, for 30 minutes daily, typically in the morning shortly after waking. The therapy is delivered through commercial light boxes designed for clinical use; the eyes must be open with light striking the retina at the appropriate intensity (verified by the box's specifications at appropriate distance), and reading or other low-attention tasks during exposure are typically permitted. The treatment is started in late autumn and continued through the winter months [77].

The meta-analytic evidence for bright light in SAD is substantial. The Golden et al. 2005 American Journal of Psychiatry meta-analysis demonstrated significant antidepressant effects in SAD with effect sizes comparable to antidepressant pharmacotherapy [78]. The Pjrek et al. 2020 Psychotherapy and Psychosomatics meta-analytic update extended the framework [79]. The effect is reliable in winter-pattern SAD with the standard protocol; effect in non-seasonal depression is more variable, with subsequent work demonstrating moderate effects for non-seasonal depression alongside but not replacing standard antidepressant treatment [80].

The clinical implementation is delivered by mental health practitioners, primary care, and increasingly by patients themselves with appropriate clinical guidance. The principal practical limits are: the daily-routine demand of 30-minute morning exposure, the cost of clinical-grade light boxes ($150–400), the risk of mood activation in patients with bipolar diathesis (a substantial concern requiring clinical assessment before initiation), and the variable patient response (the typical response rate of approximately 50–60% leaves a meaningful proportion of patients without benefit).

The chronobiology underlying light therapy for SAD remains incompletely resolved. The original conceptual frameworks invoked the phase-advance hypothesis — that SAD patients have a relative phase delay corrected by morning light's phase-advance effect — and the photon-density hypothesis — that SAD is a winter-light-deficiency syndrome with light therapy directly compensating. The current framework integrates both with the broader neurochemical effects of light on serotonergic, dopaminergic, and melatonergic systems [81]. The mechanistic ambiguity does not undermine the clinical evidence; the treatment works at meaningful magnitude regardless of which specific framework best accounts for it.

Delayed Sleep Phase Disorder and Adolescent Chronotherapy

Delayed sleep phase disorder (DSPD) is a circadian rhythm disorder characterized by sleep onset and wake times substantially later than conventional norms (sleep onset typically after 2 AM and wake time after 10 AM in the typical adult presentation), with the delayed pattern persistent, not voluntarily modifiable, and producing functional impairment when conventional schedules are required [82]. DSPD is most prevalent in adolescents and young adults, where the developmental biology of adolescent circadian delay (puberty-onset phase delay of approximately 1–2 hours; from Sleep Bachelor's and Brain Bachelor's developmental neuroscience) compounds with cultural and school-schedule factors to produce the clinical syndrome.

The clinical management of DSPD operates on the PRC framework. The core principle: a circadian system delayed relative to the desired schedule requires phase advancement, which is produced by morning bright light, evening light avoidance, and evening melatonin. The operational chronotherapy protocols include:

Scheduled morning light exposure. Bright light (10,000 lux for 30 minutes, similar to SAD protocols) within the first 30–60 minutes after the target wake time, delivered consistently across days. The light dose produces phase advances on the PRC.

Evening light avoidance. Reducing blue-light-rich evening illumination (particularly from screens, but also from interior lighting if substantial) for 2–3 hours before the target sleep time, to avoid the phase-delaying effect of evening light on the PRC.

Evening low-dose melatonin. 0.3–0.5 mg administered 5–7 hours before the target sleep time, using the phase-advance window on the melatonin PRC. The clinically effective doses for phase-shifting are substantially lower than the doses commonly used in OTC melatonin products [83].

Scheduled sleep advancement. Gradual advance of bedtime by 15–30 minutes every few days, paired with the light and melatonin interventions.

The clinical implementation is delivered by behavioral sleep medicine clinicians and pediatric sleep medicine specialists. The principal practical limits in adolescents are: the requirement for sustained protocol adherence across school and weekend days (weekend phase-delay erodes weekday advancement, the social jet lag phenomenon from Sleep Bachelor's), the practical difficulty of morning bright light exposure in the school-day morning (often before sunrise in winter at northern latitudes), and the family-system implementation challenges. The 2015 AASM practice parameter on circadian rhythm sleep-wake disorders (Auger et al.) [84] and the subsequent 2020 update [85] provide the operational guidance.

The Molecular Clock as Drug Target

The molecular clock machinery (the BMAL1/CLOCK/PER/CRY transcription-translation feedback loop from Sleep Bachelor's Lesson 2) is increasingly recognized as a potential drug-development target. Several classes of small molecules have been developed in preclinical work — REV-ERB agonists (which modulate the secondary loop of the molecular clock), CRY stabilizers, and CK1δ/ε inhibitors — with effects on circadian period and amplitude demonstrated in cell-based and animal-model systems [86][87].

The clinical translation has not yet produced approved drugs targeting the molecular clock directly. The clock-modulating drugs under development have potential applications in sleep, mood, metabolic, and oncology indications (the rationale for the latter being chronotherapy of cancer treatment timing). The pipeline is at active preclinical and early clinical stage; whether the molecular-clock-targeted approach will produce clinical interventions over the coming decade is an open question.

The chrononutrition research direction — meal timing as a peripheral-clock entrainment signal with effects on metabolic health (Scheer and colleagues at Harvard, Panda at Salk) — has produced substantial evidence that meal timing affects glucose tolerance, lipid metabolism, and weight outcomes independent of caloric intake [88][89]. The clinical translation has begun to influence dietary guidance for type 2 diabetes and metabolic syndrome, with attention to alignment of eating with the active circadian phase rather than nocturnal eating. The graduate-level clinician integrates this picture with the diet-inflammation-metabolic-mood landscape from Coach Food Master's Lesson 4 and Coach Brain Master's Lesson 4.

What This Lesson Built

Circadian medicine is one of the more clinically actionable translational stories in sleep science. The master's-level student should leave this lesson able to read a circadian-medicine paper with attention to the PRC framework underlying the intervention, the specific clinical population, the magnitude of effect, and the implementation feasibility. The student should be able to articulate the clinical protocols for jet lag, shift work disorder, SAD, and DSPD; recognize when tasimelteon for non-24-hour sleep-wake disorder is the precision-medicine indication; and engage with the molecular-clock drug-development pipeline as an active translational direction.

Lesson Check

1. Describe the principal interventions tested for shift work disorder (phase-advanced light, wake-promoting medications, melatonin, scheduling design). What is the magnitude of effect and principal limit of each?
2. Apply the Eastman-Burgess framework to a clinical case of an eastward 6-hour time-zone travel. Describe the appropriate direction of phase shift, the light-exposure schedule, the light-avoidance schedule, and the melatonin timing.
3. Define non-24-hour sleep-wake disorder and identify the patient population in which tasimelteon is FDA-approved. Why does this represent a precision-medicine success story in circadian pharmacology?
4. Describe the standard bright-light-therapy protocol for SAD (intensity, duration, timing, season). What is the principal contraindication that requires clinical assessment before initiation?
5. Outline the chronotherapy approach to delayed sleep phase disorder in an adolescent. Identify the four principal interventions (morning light, evening light avoidance, evening melatonin, scheduled sleep advancement) and the practical limits of implementation.

---

Lesson 3: Sleep Epidemiology and the Public Health of Sleep

Learning Objectives

By the end of this lesson, you will be able to:

• Describe the chronic short sleep epidemic at population data depth, citing CDC and other surveillance findings on adult and adolescent sleep duration trends, and identify the principal demographic and occupational correlates of insufficient sleep
• Articulate the IARC 2007/2019 Group 2A classification of night shift work as probably carcinogenic at translational and policy depth, identifying the principal cancer sites of concern and the methodological constraints of the underlying evidence
• Describe the school-start-time research (Wahlstrom, AAP 2014) at intervention and implementation depth, summarizing the real-world implementation findings from the Edina, Minneapolis, and subsequent district-level studies
• Articulate the sleep-mental health bidirectional relationship at epidemiological depth, citing the Baglioni 2011 systematic review and subsequent meta-analytic work on insomnia as risk factor for incident depression
• Describe drowsy driving as a public health surface, citing the AAA Foundation prevalence and crash-involvement estimates, and identify the principal occupational and demographic contexts in which the risk is most acute

Key Terms

Why Population Sleep at Master's

Up to this point in the chapter, sleep has been considered at the level of the individual: the clinical insomnia patient, the OSA patient receiving CPAP, the SAD patient using light therapy, the adolescent with DSPD. Population sleep is a different operating level. The unit of analysis is not the individual but the population, and the relevant determinants of sleep operate at population scale: occupational scheduling, school start times, neighborhood and environmental factors (noise, light pollution, housing conditions), socioeconomic stress, screen exposure patterns, and the structural arrangements of contemporary life.

Public health sleep is an active research discipline with substantial translational implications. The graduate-trained practitioner who is fluent in this material can engage informedly with the population-level interventions that affect the patients and communities they serve, and can read the contemporary literature with attention to both individual-level mechanism (covered in this chapter's prior lessons) and population-level intervention. This lesson's methodological structure parallels Coach Food Master's Lesson 1 on nutritional epidemiology — sleep epidemiology uses similar instruments (self-report on validated surveys), faces similar measurement-error constraints (the systematic divergence of self-report from objectively measured sleep), and produces similar inferential considerations (cohort-versus-RCT trade-offs, residual confounding, healthy-user effects).

The Chronic Short Sleep Epidemic

The contemporary U.S. population sleeps less than prior generations and less than current professional society recommendations. The National Sleep Foundation 2015 consensus and the American Academy of Sleep Medicine / Sleep Research Society 2015 joint consensus both recommend 7 or more hours of sleep nightly for most adults [90][91]. The CDC Behavioral Risk Factor Surveillance System (BRFSS), which has included a sleep duration question since 2009, has consistently found that approximately one-third of U.S. adults report sleeping fewer than 7 hours per night, with substantial state-level and demographic variation [92].

The demographic correlates of insufficient sleep have been characterized extensively. Black and Hispanic adults report shorter average sleep duration than non-Hispanic white adults; lower-income adults report shorter sleep than higher-income adults; adults in occupations with shift-work and irregular-schedule demands (healthcare, transportation, manufacturing, hospitality, public safety) report shorter sleep; adults in urban areas with higher noise and light pollution report shorter sleep [93][94]. The sleep health disparities literature has documented that these patterns persist after adjustment for individual-level factors and are partially attributable to structural and environmental determinants [95].

The adolescent picture is similarly concerning. The CDC Youth Risk Behavior Surveillance System has consistently found that approximately 70% of U.S. high school students sleep fewer than 8 hours on school nights (the AAP-recommended minimum for the age group is 8–10 hours) [96]. The pattern combines the developmental adolescent circadian phase delay (a biological pull toward later sleep onset) with early school start times that compress total sleep duration. The pediatric public health framing has shifted substantively over the past decade, treated in the school-start-time discussion below.

The health consequences of chronic short sleep have been documented across a substantial epidemiological literature. The associations include increased risk of cardiovascular disease, type 2 diabetes, obesity, depression and anxiety, cognitive decline, and all-cause mortality, with effect sizes that are modest individually but meaningful at population scale [97][98]. The causal-inference structure is the methodological question — short sleep is associated with these outcomes in cohort studies, but the directional and confounding picture is incompletely resolved. The bidirectional relationships (depression both produces and is produced by insomnia; obesity both produces and is produced by short sleep through OSA mediation; cognitive decline both produces and is produced by sleep disruption) complicate causal inference substantially.

The Mendelian-randomization approach to sleep duration (using genetic variants known to affect sleep duration as instruments, per the framework treated in Coach Food Master's Lesson 1) has produced evidence supporting causal contribution of short sleep to cardiometabolic outcomes, with effect estimates broadly consistent with the observational literature [99][100]. The graduate-level reader weighs the converging evidence — observational, Mendelian-randomization, mechanistic, intervention-trial — to reach calibrated conclusions about which short-sleep associations are most likely to reflect causal contribution and which may reflect reverse causation or confounding.

Shift Work as Occupational Health Issue: The IARC Classification at Translational Depth

The International Agency for Research on Cancer (IARC) classification of night shift work as probably carcinogenic to humans (Group 2A) was first issued in 2007 and reaffirmed (with continued classification) in the 2019 evaluation [101][102]. The classification was based on substantial animal evidence (genetically and behaviorally induced circadian disruption produces increased tumorigenesis in multiple rodent models) combined with limited but suggestive human epidemiological evidence (cohort studies of night shift workers, particularly nurses in the Nurses' Health Study, showing modestly elevated breast cancer incidence in long-term night shift workers).

The methodological constraints of the underlying human evidence are real and have been the focus of substantial subsequent work. The Million Women Study reported no association between shift work and breast cancer risk after extensive follow-up [103]; the meta-analytic picture has remained moderate-effect-size with substantial heterogeneity across studies. The Nurses' Health Study II analysis with updated exposure assessment found attenuated associations [104]. The IARC re-evaluation in 2019 considered this updated evidence and maintained the Group 2A classification on the basis of the broader mechanistic and animal evidence even as the human epidemiological picture was acknowledged as more constrained than the 2007 evaluation had suggested.

The policy translation of the Group 2A classification has been partial. Denmark established compensation for breast cancer in night shift workers (2008 onward) on the basis of the IARC classification [105]; several other European jurisdictions have established similar compensation frameworks; most U.S. and global jurisdictions have not produced corresponding policy. The structural workplace reform that would substantively address the carcinogenic risk — schedule design, light-exposure modification during the work shift, broader occupational-health intervention — has accumulated some evidence at intervention-trial scale (the Eastman light-protocol work from Lesson 2 of this chapter) but has not produced the systematic workplace-policy change a Group 2A classification typically catalyzes.

The graduate-level student in public health, occupational medicine, sleep medicine, or oncology engages with this material as an active translational case study. The biological evidence is substantial; the human epidemiological evidence is meaningful but constrained; the policy translation has been partial; the workplace-intervention research is developing. The case illustrates the gap between scientific evidence and population-level policy change — a gap that is structural in many public health translations and that requires sustained engagement to bridge.

Pediatric Sleep and the School-Start-Time Research

The school start time research is one of the cleaner translational stories in adolescent sleep epidemiology. Kyla Wahlstrom at the University of Minnesota produced foundational longitudinal work in the late 1990s and 2000s following the Edina (1996) and Minneapolis (1997) school district decisions to shift high school start times from 7:20 AM to 8:30 AM and from 7:15 AM to 8:40 AM respectively [106][107]. The Wahlstrom findings — consistent improvement in attendance, decreased tardiness, increased graduation rates, improved standardized test scores, decreased self-reported sleep disturbance, and (most concerningly) decreased adolescent depression and substance use — established the framework that has driven subsequent policy advocacy.

The American Academy of Pediatrics 2014 policy statement School Start Times for Adolescents formally recommended that middle and high schools start no earlier than 8:30 AM, on the basis of the accumulated developmental, neurobiological, and educational research [108]. The recommendation has been substantially influential; numerous state legislatures and individual school districts have considered or implemented start-time delays in the subsequent decade.

The California 2019 statewide law (SB 328) — requiring middle schools to start no earlier than 8:00 AM and high schools no earlier than 8:30 AM, with implementation by 2022 — was the first U.S. state-level legislation on the topic and has produced one of the cleanest natural-experiment opportunities to study the population-level effects [109]. Preliminary outcome research from the California implementation has been favorable on educational, mental health, and traffic-safety outcomes; longer-term follow-up is ongoing.

The implementation challenges are substantial and predictable. After-school schedules (athletics, employment, family caregiving), transportation logistics, and the cascade effects on elementary schools (which sometimes shift earlier to accommodate the bus system) all complicate implementation. The Owens et al. 2014 Journal of Adolescent Health practical-implementation paper documented these challenges and proposed frameworks for managing them [110]. The contemporary picture is that the science is settled — delayed school start times improve adolescent sleep duration and a range of associated outcomes — and the implementation is variable across districts and states, with the question of who will adopt the change and how rapidly remaining the principal translational question.

Sleep and Mental Health: The Bidirectional Relationship

The bidirectional relationship between sleep disruption and mood disorders is among the most robust findings in clinical and population mental health. The Baglioni et al. 2011 Journal of Affective Disorders systematic review and meta-analysis is the landmark synthesis: prospective epidemiological studies consistently demonstrate that insomnia at baseline predicts incident major depressive disorder over follow-up, with relative risks of approximately 2.0–2.6 across studies and substantial replication [111]. The directional association is robust and has been confirmed in subsequent meta-analytic updates [112].

The bidirectional nature of the relationship is also well-established. Insomnia predicts incident depression; depression produces insomnia; the conditions are highly comorbid in cross-sectional samples (insomnia is a DSM diagnostic feature of major depression and persists in approximately 40–60% of patients in clinical remission of depressive episodes) [113]. The sleep-and-suicide literature has accumulated evidence that sleep disturbance is a transdiagnostic risk factor for suicidal ideation and behavior, with effect sizes that remain meaningful after adjustment for depression severity and other mental health symptoms [114][115]. Insomnia is the most consistently documented sleep-related risk factor for suicide across populations and methodologies.

The clinical translation of this picture has begun to shape treatment frameworks. The Manber et al. 2008 Sleep RCT demonstrated that adding CBT-I to standard antidepressant treatment in patients with comorbid insomnia and depression improved both insomnia and depression outcomes compared to antidepressant treatment alone [116]; subsequent work has extended the framework to suicidal-risk populations [117]. The graduate-trained mental health practitioner increasingly recognizes sleep disruption not as a casual "lifestyle" complaint to be deferred but as a clinical signal warranting specific assessment and treatment.

The cross-reference to Coach Brain Master's Lesson 4 on the inflammatory hypothesis of depression operates here at lateral lesson-level resolution. The sleep-inflammation-mood triangle integrates: chronic sleep disruption produces systemic low-grade inflammation; systemic inflammation contributes to depression in a subgroup of patients; the integrated picture suggests that sleep intervention may operate partially through inflammation modulation, and that inflammation-targeted depression treatment may need to address sleep concurrently. The 2019 Irwin and Opp Nature Reviews Neuroscience review articulated this framework comprehensively [118]; the clinical translation is at active research stage.

Drowsy Driving as Life-Safety Public Health

Drowsy driving is a public health surface that deserves explicit master's-level attention because it is both prevalent and lethal, and because the master's-trained practitioner will encounter the issue clinically (patients with shift work, with untreated OSA, with chronic short sleep) and may bear responsibility for the appropriate clinical communication.

The AAA Foundation for Traffic Safety has produced the most comprehensive U.S. epidemiology of drowsy driving. The Foundation's surveillance work has consistently estimated that approximately one in six fatal crashes involves a drowsy driver — an estimate that exceeds earlier NHTSA estimates and that aligns with naturalistic-driving-study evidence from the SHRP2 program [119][120]. Approximately one in three U.S. drivers report having driven while drowsy in the prior month in survey research; approximately one in twenty report having fallen asleep at the wheel in the prior month [121].

The physiological basis of drowsy driving impairment is the loss of vigilance, attention, and reaction time produced by sleep loss and circadian misalignment. The Williamson and Feyer 2000 study demonstrated that 17–19 hours of sustained wakefulness produces driving impairment equivalent to a blood alcohol concentration of approximately 0.05–0.08% [122]; 24 hours of sustained wakefulness produces impairment comparable to legally intoxicated driving. The clinical translation is direct: extended wakefulness is a per-se driving impairment, not merely an additional risk factor.

The populations at elevated risk are shift workers (particularly night-shift and rotating-shift workers), commercial drivers (the Federal Motor Carrier Safety Administration regulates hours-of-service for commercial drivers explicitly because of drowsy-driving risk), individuals with untreated OSA (a substantial elevated-crash-risk surface that has produced FMCSA-level policy on commercial-driver OSA screening), adolescents (the combined effect of circadian phase delay, early school start times, and inexperienced driving), and patients on sedating medications (the BZ-opioid co-prescription risk from Lesson 1 of this chapter intersects directly with driving safety).

The clinical communication for drowsy driving with patients at elevated risk is part of competent sleep-adjacent practice. The graduate-level practitioner does not prescribe driving restrictions — that is the role of the licensed clinician within appropriate clinical relationship — but the practitioner who recognizes the risk profile and engages with patients about it operates within scope and contributes meaningfully to safer practice. The conversation should include: the magnitude of the risk, the practical strategies for managing it (avoiding driving in vulnerable periods, using public or rideshare transportation after long shifts, recognizing the warning signs of drowsy driving — frequent yawning, drifting from lane, missing exits), and the referral pathway when the underlying contributor (chronic short sleep, untreated OSA, medication effects) is modifiable.

What This Lesson Built

The graduate-level public-health-sleep student should leave this lesson with several capacities: the ability to read a population-sleep study with attention to instrument validity and measurement-error structure paralleling the nutritional epidemiology framework; the ability to evaluate the IARC night shift classification at translational/policy depth; the ability to engage with the school-start-time research and the implementation literature; the ability to integrate the sleep-mental-health bidirectional relationship into clinical and public-health thinking; and the ability to engage with drowsy driving as a life-safety clinical communication surface.

Lesson Check

1. Describe the chronic short sleep epidemic at population data depth, citing the CDC BRFSS findings and identifying the principal demographic and occupational correlates of insufficient sleep.
2. Articulate the IARC Group 2A classification of night shift work and identify two specific cancer sites of concern. What are the methodological constraints of the human epidemiological evidence, and what does the policy translation look like?
3. Summarize the Wahlstrom school-start-time research and the AAP 2014 policy recommendation. What are the principal real-world outcomes documented in implementing districts, and what is the principal implementation challenge?
4. Describe the Baglioni 2011 meta-analytic finding on insomnia as risk factor for incident depression. How has this framework shaped contemporary treatment of comorbid insomnia and depression?
5. Articulate drowsy driving as a public health surface, citing the AAA Foundation estimates and the Williamson-Feyer equivalence between extended wakefulness and alcohol impairment. Identify three populations at elevated risk.

---

Lesson 4: Sleep, Aging, and Neurodegenerative Disease

Learning Objectives

By the end of this lesson, you will be able to:

• Describe the principal changes in sleep architecture across the lifespan (slow-wave sleep decline, increased fragmentation, advanced sleep phase, REM preservation versus reduction) and articulate the clinical implications for older-adult sleep medicine
• Describe the glymphatic clearance hypothesis at translational research depth, tracing the Iliff 2012 and Xie 2013 foundational work through the Lucey et al. 2022 Annals of Neurology slow-wave-activity-in-preclinical-AD finding, and identify what the glymphatic framework does and does not yet establish
• Articulate the Aβ-sleep bidirectional relationship, drawing on the Holtzman laboratory work, and identify the causal-inference challenges that constrain the translational picture
• Describe REM behavior disorder as α-synucleinopathy prodrome at longitudinal cohort depth, citing the Postuma 2019 Brain finding on conversion rates and articulating the clinical implications for early detection
• Articulate the integrated sleep-inflammation-cognition-mood translational territory, integrating the lessons across this chapter and the Brain Master's Lesson 4 inflammatory depression material

Key Terms

Why Sleep and Aging at Master's

The sleep-and-aging picture is one of the more substantial translational research directions in contemporary clinical neuroscience. The convergent evidence — that sleep changes precede clinical neurodegenerative disease, that sleep disruption may contribute mechanistically to neurodegeneration through glymphatic and inflammatory pathways, and that REM behavior disorder is a prodromal marker for α-synucleinopathies with substantial predictive validity — has produced an active translational landscape with both research opportunities and clinical implications.

This lesson connects substantively to Coach Brain Master's Lesson 4 on the inflammatory hypothesis. The sleep-inflammation-cognition-mood territory is the integrated translational space where multiple master's-level research directions converge. The graduate-level practitioner who is fluent in the lesson's content can engage with the populations at the sleep-cognition-mood intersection — older adults, patients with mild cognitive impairment, individuals with established neurodegenerative disease, caregivers — with substantial depth.

Sleep Architecture Changes Across the Lifespan

The systematic developmental and aging changes in sleep architecture have been characterized in detail across multiple meta-analyses, with the Ohayon et al. 2004 Sleep meta-analysis providing the foundational synthesis [123]. The principal changes:

Slow-wave sleep (N3) declines substantially with age. Young adults typically have approximately 15–20% of total sleep time in N3; by age 60–70, N3 represents approximately 5–10% of total sleep time; by age 80+, N3 may be reduced to less than 5%. The decline is most prominent in the first sleep cycle (where young adults concentrate most of their N3) and reflects reduced slow-wave amplitude and slow-wave-density rather than complete absence of N3 [124]. The mechanistic basis includes reduced cortical synchronization, prefrontal gray-matter volume changes, and altered thalamocortical oscillatory dynamics.

Sleep fragmentation increases. The number of awakenings and arousals per hour of sleep increases with age; total wake-after-sleep-onset (WASO) increases; sleep efficiency declines. The increased fragmentation contributes to subjective non-restorative sleep complaints common in older adults [125].

Sleep phase advances. Older adults tend toward earlier bedtimes and earlier morning awakenings; the average phase advance from young adulthood to older adulthood is approximately 1–2 hours. The advance reflects circadian-system changes including reduced amplitude of the core-temperature rhythm and reduced melatonin amplitude [126].

REM sleep is relatively preserved. Although the absolute amount of REM may decline modestly, the proportion of REM in total sleep time is relatively preserved across the lifespan compared to the more dramatic N3 decline. The REM preservation has clinical implications including the appearance of dream-enactment behaviors in older adults with RBD.

Clinical implications of these changes include the appropriate clinical framing for patient complaints (the typical patient narrative of "I used to sleep 8 hours straight and now I wake up at 4 AM" reflects normal aging at one level, but warrants assessment for underlying clinical contributors including OSA, depression, medication effects, and primary insomnia); the dosing-and-pharmacology considerations for sleep medications in older adults (reduced clearance, increased sensitivity to GABA-A modulation, fall risk, the Beers Criteria recommendations on inappropriate prescribing); and the broader recognition that sleep disturbance in older adults is a clinical signal warranting systematic assessment rather than dismissal as normal aging [127].

The Glymphatic Clearance Hypothesis

The glymphatic system is the brain's perivascular fluid clearance pathway, characterized principally by Maiken Nedergaard and Jeffrey Iliff at the University of Rochester (now Copenhagen). The 2012 Science Translational Medicine paper A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β established the framework [128]. CSF enters the brain along peri-arterial spaces, exchanges with interstitial fluid through aquaporin-4 (AQP4) water channels on astrocyte endfeet, distributes through the parenchyma, and drains via peri-venous routes. The system clears soluble metabolites including Aβ, tau, and other proteins relevant to neurodegeneration.

The 2013 Science paper by Xie et al., Sleep drives metabolite clearance from the adult brain, demonstrated that glymphatic activity is substantially elevated during sleep relative to waking — interstitial space increases approximately 60% during sleep, and Aβ clearance approximately doubles [129]. The finding established a mechanistic framework for sleep's role in neurodegenerative disease risk: insufficient sleep reduces glymphatic clearance of Aβ, increased Aβ accumulation contributes to AD pathophysiology, and a sleep-AD positive-feedback loop emerges.

The framework has been substantially influential and is widely cited in both research and lay-public contexts. The methodological constraints of the framework should also be acknowledged at master's level. The original Iliff and Xie work was conducted principally in rodents; the translation to humans has been more difficult than the elegant mouse-model findings initially suggested. Some elements of the glymphatic framework — particularly the magnitude of fluid flow through perivascular spaces, the relative contribution of bulk flow versus diffusion, the specific role of AQP4 in driving the exchange — have been challenged in subsequent work [130][131]. The Smith and Verkman 2018 eLife paper questioned whether the glymphatic flow magnitudes proposed by the original framework were biophysically plausible [132]; subsequent work has continued to refine the picture without producing definitive resolution.

A master's-level reader of the glymphatic literature holds both the substantial translational excitement and the methodological constraints simultaneously. The framework is real, important, and has produced testable predictions that have largely been borne out in human work (treated below). The strongest claims for the framework's universality and quantitative magnitudes are not fully settled, and graduate engagement reads the literature with appropriate calibration.

The Lucey 2022 Annals of Neurology Finding

The Lucey et al. 2022 Annals of Neurology paper, Sleep and longitudinal cognitive performance in preclinical and early symptomatic Alzheimer's disease, is among the most consequential clinical translations of the glymphatic framework [133]. The study used overnight polysomnography combined with CSF Aβ and tau measurement and longitudinal cognitive assessment in older adults across the AD spectrum.

The principal findings: reduced slow-wave activity (specifically the 1–4 Hz delta power) was associated with elevated CSF tau and with longitudinal cognitive decline in preclinical AD; the association persisted after adjustment for total sleep time, age, and other potential confounders; the slow-wave activity reduction preceded cognitive impairment in time. The framework supports the hypothesis that sleep architecture changes — particularly slow-wave activity disruption — are part of the early AD pathophysiology rather than merely a downstream consequence of established disease.

The translational implications are substantial. If slow-wave activity is part of the early pathophysiology, then interventions that enhance slow-wave activity (acoustic stimulation during sleep, pharmacological approaches under development, behavioral interventions) might produce disease-modifying effects rather than merely symptomatic improvement. The contemporary work on acoustic enhancement of slow-wave activity (Papalambros et al. 2017 Frontiers in Human Neuroscience and subsequent work) has demonstrated proof-of-concept enhancement with effects on memory consolidation, with the translational extension to AD-relevant outcomes at active research stage [134][135].

The Aβ-Sleep Bidirectional Relationship

David Holtzman and colleagues at Washington University have produced foundational work on the bidirectional relationship between Aβ and sleep. The 2009 Science paper Amyloid-β dynamics are regulated by orexin and the sleep-wake cycle demonstrated that interstitial Aβ concentrations rise during wakefulness and fall during sleep in both mouse models and human CSF measurements, with the rise-and-fall pattern dependent on orexin signaling [136]. Subsequent work has extended the framework to demonstrate that chronic sleep deprivation in mouse models accelerates Aβ plaque formation, and that orexin antagonism (the suvorexant pharmacology covered in Lesson 1 of this chapter) reduces Aβ accumulation [137].

The human translation of this work has produced converging evidence. The Lucey 2018 Annals of Neurology paper demonstrated elevated CSF Aβ42 after one night of sleep deprivation in healthy adults [138]. The Spira 2013 JAMA Neurology paper found cross-sectional associations between shorter self-reported sleep duration and elevated amyloid burden on PET imaging in cognitively normal older adults [139]. The Ju et al. 2017 Brain paper demonstrated that one night of slow-wave-sleep disruption (without changes in total sleep time) increased CSF Aβ42 in healthy adults — establishing slow-wave sleep specifically as the relevant intervention target rather than total sleep time alone [140].

The causal-inference challenges of this picture should be acknowledged at master's level. The Aβ-sleep relationship is bidirectional in mechanism: sleep disruption increases Aβ accumulation through reduced glymphatic clearance; Aβ accumulation produces sleep disruption through both pathophysiology in sleep-regulating brain regions and through neuropsychiatric symptoms common in early AD. Disentangling the causal direction in observational human studies is methodologically difficult; the converging evidence (animal mechanistic work, human acute intervention studies, observational cohort work, Mendelian-randomization approaches that are still maturing) supports a meaningful causal contribution of sleep disruption to AD pathophysiology while acknowledging that the bidirectional dynamics complicate the picture.

The clinical translation has begun to influence practice. The American Academy of Sleep Medicine and adjacent professional society guidance increasingly recognizes sleep disturbance as a modifiable contributor to cognitive aging outcomes; the 2024 Lancet Commission on Dementia Prevention, Intervention, and Care included sleep among the modifiable risk factors with substantial attributable-risk estimates [141]. Whether sleep intervention in midlife will produce population-level reductions in AD incidence is the open translational question; the trial designs that would answer it are at active development stage.

REM Behavior Disorder as α-Synucleinopathy Prodrome

The REM behavior disorder (RBD) clinical literature has produced one of the strongest prodromal markers in contemporary neurology. The framework, treated at Bachelor's depth in Sleep Bachelor's, traces from the Schenck and Mahowald 1986 JAMA original case series describing the disorder, through the recognition that idiopathic RBD predicts subsequent α-synucleinopathy at very high rates, to the Postuma et al. 2019 Brain longitudinal cohort paper documenting conversion rates [142][143].

The Postuma 2019 cohort followed 1,280 patients with polysomnography-confirmed idiopathic RBD across multiple international centers for an average of 4.6 years. The cumulative phenoconversion rate to defined α-synucleinopathy (Parkinson's disease, dementia with Lewy bodies, multiple system atrophy) was approximately 6% per year, with 14-year cumulative conversion approaching 75–80%. The conversion is to defined clinical disease, not merely to research-defined biomarker status; most patients with idiopathic RBD followed for sufficient duration develop α-synucleinopathy.

The clinical translation of this framework has implications for both neurology practice and for individual patient counseling. The RBD diagnosis carries substantial prognostic weight; the patient and family deserve information about the prognostic implications delivered with appropriate clinical skill. The neuroprotective-trial research direction has been substantial — the framework that disease-modifying interventions tested in idiopathic RBD might prevent or delay clinical α-synucleinopathy has driven multiple Phase 2 trials of candidate neuroprotective agents [144]. As of this writing, no neuroprotective intervention has produced definitive evidence of disease-modification; the framework remains an active translational direction.

The clinical communication with patients about RBD prognosis is sensitive and clinically demanding. The information is real (the conversion rate is well-established and high), the clinical implications are substantial (motor and cognitive decline are likely outcomes over time), and the lack of currently approved disease-modifying interventions limits the actionable response. The neurology and sleep medicine practitioners who deliver this information do so within established clinical relationships with appropriate clinical skill. The graduate-trained adjacent practitioner who recognizes the RBD-α-synucleinopathy framework can engage with patients and families informedly about the broader clinical picture, never substituting for the prescribing or counseling clinician.

The IARC Night Shift Classification Revisited at Oncology Translational Depth

The IARC Group 2A classification (treated at policy depth in Lesson 3 of this chapter) intersects with the sleep-and-cancer translational research direction. The mechanistic hypotheses for night-shift-associated cancer risk include: melatonin suppression by nocturnal light exposure (the original Stevens hypothesis from 1987) [145]; circadian disruption of cell-cycle regulatory genes; reduced glymphatic clearance and increased systemic inflammation; metabolic dysregulation from circadian-misaligned eating patterns.

The translational research on these mechanisms has accumulated steadily. The Stevens hypothesis specifically — that nocturnal melatonin suppression contributes to hormone-sensitive cancer risk through reduced melatonin-mediated antiestrogenic effects — has been investigated extensively with mixed support [146]. The broader circadian-disruption framework has gained mechanistic support from cell and animal model work demonstrating that key tumor suppressors (TP53) and proliferation-regulatory genes are circadian-clock-regulated, and that circadian disruption affects tumorigenesis in defined animal models [147].

The chronotherapy of cancer treatment — timing chemotherapy delivery to circadian phases that maximize tumor effect and minimize toxicity to healthy cells — is an active translational research direction with several decades of accumulated work [148]. Specific applications in colorectal cancer (the irinotecan and 5-FU chronomodulated protocols developed by Lévi and colleagues) have demonstrated improved tolerability and in some studies improved outcomes [149]. The translation to broader clinical practice has been gradual; routine chronotherapy is not standard in most contemporary oncology care, but the framework continues to inform research direction.

The graduate-level student engages with this material as the active translational landscape it is. The sleep-cancer connection has substantive mechanistic grounding, meaningful epidemiological evidence with acknowledged constraints, and a translational pipeline that has produced specific applications without yet producing population-level practice change.

The Sleep-Inflammation-Cognition-Mood Integration

The integrative picture at the close of this lesson connects sleep to inflammation, cognition, and mood — territory that crosses Coach Brain Master's Lesson 4 directly. The Irwin 2019 Nature Reviews Neuroscience synthesis articulates the framework [118]: chronic sleep disruption produces low-grade systemic inflammation through HPA axis dysregulation, sympathetic nervous system activation, and altered cytokine signaling; the resulting inflammatory state contributes to depression, cognitive decline, and cardiometabolic disease through the mechanisms covered across these chapters. Acute sleep interventions reduce inflammatory markers in some studies; chronic sleep improvement may produce broader downstream benefits.

The integrated framework is methodologically demanding to evaluate because of the many bidirectional relationships involved (sleep ↔ inflammation, inflammation ↔ depression, depression ↔ sleep, depression ↔ cognition, sleep ↔ cognition, all simultaneously). The graduate-level reader engages with the literature with appropriate calibration: meaningful mechanistic grounding, accumulating evidence, but causal-inference structure that remains complex and that limits the strength of clinical-translation claims that any single intervention will produce the full integrated benefit.

Lesson Check

1. Describe the principal sleep architecture changes across the adult lifespan (slow-wave sleep, fragmentation, phase, REM). What are the clinical implications for older-adult sleep medicine and sleep-medication prescribing?
2. Trace the glymphatic clearance framework from Iliff 2012 / Xie 2013 through the contemporary literature. What are the strongest pieces of supporting evidence, and what are the principal methodological constraints?
3. Describe the Aβ-sleep bidirectional relationship at the level of: the Holtzman foundational mouse-model work, the human acute sleep-deprivation findings, and the cross-sectional epidemiological work. What causal-inference challenges complicate the picture?
4. Summarize the Postuma 2019 Brain cohort findings on idiopathic RBD conversion to α-synucleinopathy. What are the cumulative conversion rates at 14-year follow-up, and what are the clinical implications for early detection?
5. Articulate the sleep-inflammation-cognition-mood integration as a translational framework, drawing on lateral references to Brain Master's Lesson 4. What is the principal methodological challenge to evaluating the integrated framework?

---

Lesson 5: Sleep Research Methods at Translational Depth

Learning Objectives

By the end of this lesson, you will be able to:

• Describe the contemporary sleep measurement hierarchy — polysomnography, actigraphy, consumer wearable — at clinical practice depth, articulating the de Zambotti 2019 validity-gap framework at master's-translational resolution
• Articulate the structural limits of sleep deprivation paradigms (total versus chronic partial; the Van Dongen 2003 framework and its translational constraints) and identify the implications for translating sleep research to clinical and real-world contexts
• Apply the five-point evaluation framework to specific contemporary sleep claims (the "athletes need 10 hours" claim, polyphasic sleep claims, sleep tracker accuracy claims, the magnesium-for-sleep supplement landscape)
• Describe the publication bias picture in sleep medicine clinical trials and identify the specific structural features of the field that complicate evaluation of the published literature
• Articulate the master's-level posture toward sleep claims: hold strong evidence with appropriate confidence, hold weak evidence with appropriate skepticism, recognize what remains genuinely unsettled

Key Terms

Why Methods at the Chapter's Close

A graduate chapter on clinical sleep medicine and circadian translation cannot close without explicit engagement with the field's methodological infrastructure. The lessons of the prior four — the treatment landscape, circadian medicine, population sleep, sleep and aging — all rest on the underlying research-methods foundation. The graduate-level student who can apply methodological discipline to any sleep claim is positioned to engage with the rapidly-evolving sleep-tracking and sleep-product industry, the patient-facing claims that flood lay-media coverage, and the clinical-translational research that will shape practice over the coming decade.

This lesson's methodological structure parallels Coach Food Master's Lesson 1 and Coach Brain Master's Lesson 5 as the closing-lesson translational-methods anchor. The five-point framework that has operated across this chapter and across Food Master's and Brain Master's becomes, by the end of this lesson, the everyday operating tool of master's-level engagement with the sleep-and-circadian literature.

The Sleep Measurement Hierarchy

Sleep measurement spans a clinical-and-research hierarchy that the graduate-level practitioner needs to navigate fluently.

Polysomnography (PSG) remains the clinical gold standard. The full PSG montage from Sleep Bachelor's Lesson 5 — multichannel EEG, EOG, EMG of the chin and (in suspected RBD evaluation) of the limbs, respiratory effort belts at thorax and abdomen, oronasal airflow, pulse oximetry, ECG, body position, and audio/video — provides comprehensive characterization of sleep architecture, respiratory events, periodic limb movements, parasomnias, and associated physiology [150]. PSG is required for the diagnosis of OSA in many guidelines (with HSAT as an acceptable alternative in defined patient populations), for the diagnosis of RBD (where the documentation of REM-sleep-atonia loss is the diagnostic finding), for evaluation of complex parasomnias, and for the characterization of seizures with suspected nocturnal components. The clinical limits are: cost, availability, the "first-night effect" of sleeping in an unfamiliar laboratory environment, and the snapshot nature of single-night assessment relative to typical-night patterns.

Home Sleep Apnea Testing (HSAT) is a reduced-channel study using only the respiratory measures (airflow, effort, oximetry) without the neurophysiological montage. The technique provides accurate AHI estimation in patients with high pre-test probability of OSA but cannot characterize sleep stages or detect other sleep disorders [151]. HSAT has expanded substantially as a triage and screening tool, particularly during and after the COVID-19 pandemic which constrained in-laboratory testing access.

Actigraphy is the wrist-worn accelerometry standard for estimating sleep-wake patterns over multiple days to weeks. Research-grade actigraphs (Philips Actiwatch, ActiGraph, MotionWatch) with validated algorithms provide accurate estimates of total sleep time and sleep efficiency in healthy adults and many clinical populations, with the principal limitation being the inability to distinguish quiet wakefulness from sleep (the device records both as "non-active") [152]. The accuracy is sufficient for circadian rhythm characterization, for chronic insomnia evaluation, and for tracking treatment response across days to weeks. The 2018 AASM clinical practice guideline on actigraphy formalized appropriate use [153].

Consumer sleep wearables — Fitbit, Apple Watch, Oura Ring, Whoop, Garmin, and the broader category — have proliferated substantially over the past decade. The devices integrate accelerometry with photoplethysmography (PPG) for heart rate and heart rate variability assessment, sometimes with skin temperature sensing, into proprietary algorithms that estimate sleep duration, sleep stages, and various derived metrics. The validity picture against PSG has been characterized in detail in the de Zambotti et al. 2019 Chronobiology International review and subsequent updates [154][155]: the consumer wearable accuracy for total sleep time is reasonable (typically within 15–30 minutes of PSG in healthy adults at the population level, with substantial individual-level error); the accuracy for sleep stages is substantially poorer, with the devices systematically over-estimating deep sleep, under-estimating REM, and producing stage-specific error patterns that are not stable across patients or across nights; the accuracy for measuring clinical sleep disorders is limited, with the devices not reliably detecting OSA or other clinical conditions.

The clinical implications of the wearable validity picture are several. The devices are useful for trend-level tracking of total sleep time and bedtime/wake-time regularity. They are not reliable substitutes for clinical PSG when clinical sleep disorder is suspected. The patient-facing presentation of detailed sleep-stage information without appropriate validity context can produce both unwarranted reassurance ("my deep sleep is fine") and unwarranted alarm ("my REM sleep is too short"). The graduate-level clinician engaging with patients using consumer wearables provides the appropriate framing: useful trend-level information at the night-to-night and week-to-week level, not a substitute for clinical evaluation when clinical concern exists, and the stage-specific information should not be treated as comparable to PSG-derived metrics.

The orthosomnia phenomenon — patients who develop or worsen insomnia symptoms in response to anxiety about their consumer-tracker sleep data — was first described by Baron et al. 2017 in the Journal of Clinical Sleep Medicine [156]. The phenomenon illustrates the broader translational principle: consumer health-tracking technologies can produce real harm when they generate clinical concern beyond what the underlying measurement supports. The graduate-trained practitioner engaging with patients who present with consumer-tracker-driven sleep concerns provides clinical context, redirects appropriately to validated measurement when indicated, and addresses the underlying anxiety pattern that the tracker has surfaced.

Sleep Deprivation Paradigms and Their Translational Limits

The sleep deprivation research paradigm has been the workhorse of experimental sleep research for decades. The two principal forms — total versus chronic partial — produce different effects and support different inferential claims.

Total sleep deprivation (24–72 hours of sustained wakefulness) produces dramatic and well-characterized effects on cognition, mood, metabolism, and physiology. The classic findings — degraded vigilance, attention, working memory, decision-making, emotional regulation, and physical performance — are robust across decades of research. The translational limits are that total sleep deprivation is rarely the real-world clinical or population sleep problem (outside specific occupational contexts and acute medical-emergency situations). What the population actually experiences is chronic partial sleep restriction, which produces a distinct effect pattern.

Chronic partial sleep deprivation is the more clinically relevant paradigm and has been extensively studied since the Van Dongen et al. 2003 Sleep landmark paper The cumulative cost of additional wakefulness [157]. Van Dongen restricted healthy adults to 4, 6, or 8 hours in bed for 14 consecutive nights and measured cognitive performance (psychomotor vigilance task) and subjective sleepiness. The principal findings: cognitive performance decrements at the 4-hour and 6-hour restriction levels accumulated across days, with the 4-hour group reaching impairment equivalent to total sleep deprivation by day 14 and the 6-hour group reaching equivalent to 24 hours of total sleep deprivation by day 14. Critically, subjective sleepiness ratings did not track with objective performance decrements — participants under-estimated their impairment progressively as the restriction continued.

The Van Dongen finding has been replicated and extended. The subjective-objective dissociation is particularly important: chronic short sleep produces functional impairment that the individual does not subjectively recognize, an effect that has substantial implications for shift workers, college students, and the broader population segments experiencing chronic short sleep.

The translational limits of the Van Dongen paradigm and similar work include: the laboratory setting differs from real-world sleep restriction, where individuals typically have varying sleep durations across days and can sometimes "catch up" on weekends; the healthy young adult populations studied may not represent the broader clinical and population sleep landscape; the cognitive outcomes measured (vigilance, attention) may not capture the full range of relevant real-world functional outcomes; and the typical 14-day protocols do not capture the multi-year chronic short sleep pattern characteristic of the population epidemic. The graduate-level reader engages with the deprivation paradigm literature as the laboratory-experimental evidence base it is — strong on causal inference within its constraints, more limited on direct translation to the population-level question.

The "can you catch up on weekends" question has been investigated specifically. The Pejovic et al. 2013 American Journal of Physiology paper demonstrated that two recovery nights after chronic restriction did not fully restore cognitive performance to baseline [158]. The Depner et al. 2019 Current Biology paper used a more comprehensive metabolic and cognitive battery to show similar incomplete recovery [159]. The aggregated evidence suggests that the catch-up sleep effect is real but incomplete; weekend recovery sleep can partially offset weekday restriction effects, but the partial offset is not full restoration. The population-level translation: chronic mid-week short sleep with weekend catch-up is not a neutral pattern, even when total weekly sleep matches recommended duration.

The Five-Point Framework Applied to Specific Sleep Claims

The five-point evaluation framework — design, population, measurement, effect size, replication status — is the everyday operating tool of master's-level sleep-claim evaluation. Applied to several specific claims:

Claim: "Athletes need 10 hours of sleep nightly." The underlying research traces to Cheri Mah and colleagues at Stanford [160]: extending sleep duration in collegiate basketball players from approximately 6.8 hours to approximately 10 hours over 5–7 weeks produced improvements in sprint times, free-throw and three-point shooting accuracy, and reaction time. The framework: design is a within-subjects pre-post extension protocol with small sample size; population is collegiate male basketball players who were sleep-restricted at baseline; measurement is performance-task outcomes with limited blinding; effect size is meaningful in this specific population; replication has been mixed across sports and populations. The translation: athletes who are currently sleep-restricted likely benefit from sleep extension; the specific claim of "10 hours" reflects the extension protocol's design rather than an underlying physiological requirement; and the broader athletic-recovery framework is supported with appropriate caveats about individual variation.

Claim: "Polyphasic sleep allows you to function on 2–4 hours per day." The underlying evidence base is essentially absent at intervention-research depth. The framework: no adequate clinical trials of polyphasic sleep schedules; available evidence (small case series, self-experimentation reports) provides no causal-inference grade evidence and no characterization of long-term effects; the broader sleep deprivation research (Van Dongen and successors) suggests that chronic restriction below approximately 6 hours produces accumulating cognitive impairment; the population in polyphasic-sleep advocacy claims is non-representative (typically young, otherwise-healthy, motivated self-experimenters); replication status is minimal. The translation: the polyphasic sleep claim is not supported by adequate evidence at any of the five framework points, and the available adjacent evidence (chronic sleep restriction research) directly contradicts the claim. The graduate-trained practitioner can engage with patients about this claim with the appropriate framing: the claim is not supported by available research, and the broader literature suggests the practice is likely to produce accumulating functional impairment.

Claim: "Sleep trackers accurately measure your sleep stages." From the de Zambotti review framework: the underlying evidence demonstrates that consumer wearables produce systematically biased stage estimates compared to PSG, with reasonable accuracy for total sleep time but poor accuracy for stage characterization. The claim that a consumer device "accurately" measures sleep stages overstates what the evidence supports. The translation: trend-level total sleep time tracking is appropriate use; stage-level interpretation should not be treated as comparable to PSG-derived data.

Claim: "Magnesium supplementation improves sleep." The underlying evidence base for magnesium-for-sleep is small (the principal randomized trials are short-duration, small-sample studies in selected populations), with reported effects on subjective sleep quality of modest magnitude [161]. The framework: design is RCT but with substantial limitations (sample size, blinding, outcome measurement, duration); population is variable across studies; measurement relies on subjective scales; effect size is small; replication is limited. The translation: the magnesium-for-sleep claim has very modest evidence support; the marketing of magnesium supplements for sleep substantially outruns the research base; the relatively favorable safety profile of magnesium supplementation in healthy adults means the practice is unlikely to produce harm in most users, but the framing of the practice as evidence-supported requires the appropriate calibration.

The framework applied transparently produces calibrated assessments of any specific claim. The graduate-level student leaves this lesson fluent in the framework and able to apply it across the contemporary sleep-claim landscape.

Publication Bias in Sleep Medicine

Publication bias in sleep medicine clinical trials follows the broader medical pattern documented at landmark depth by Turner et al. 2008 NEJM for antidepressant trials (treated at depth in Coach Brain Master's Lesson 5) [162]. The specific structural features of sleep medicine that affect the publication-bias picture include:

Subjective outcomes dominate the published literature. Sleep medicine trials frequently use subjective sleep-quality scales (PSQI, ISI, sleep diaries) as primary outcomes. These outcomes are vulnerable to expectancy and unblinding effects in trials where blinding is difficult (most behavioral interventions; the dose-distinct DORA versus placebo effects; the light-therapy intensity variations). The published literature in these areas should be read with awareness that the subjective-outcome effects are typically larger than objective-outcome effects in matched trials.

Industry-sponsored trial concentration. A substantial fraction of sleep-medication clinical trials are industry-sponsored, with the structural features of industry sponsorship that have been documented to produce systematic publication-bias and outcome-reporting bias (Bes-Rastrollo framework from Coach Food Master's Lesson 4) [163]. The recent dual orexin receptor antagonist literature has been substantially industry-developed, with the appropriate critical reading discipline applied to the magnitude of claimed effects.

Behavioral intervention publication bias. CBT-I and behavioral sleep medicine trials are typically conducted by academic groups without industry sponsorship, but the publication pattern shows the typical positive-result skew that characterizes much of clinical psychology research. The meta-analytic literature (Trauer 2015 and successors) has incorporated funnel-plot and statistical-correction approaches with continuing-but-meaningful magnitude estimates [164].

The newer trial-registration environment has improved the situation prospectively. ClinicalTrials.gov registration is required for major journal publication; the WHO International Clinical Trials Registry Platform extends the requirement internationally; the EQUATOR Network reporting standards (CONSORT for RCTs, PRISMA for systematic reviews) have improved transparency in current trials. The historical published record on which much of contemporary sleep medicine guidance rests retains the bias the older era produced; the graduate-trained reader weighs current-era trial evidence and historical-era trial evidence accordingly.

The Master's-Level Posture Toward Sleep Claims

Sleep science and sleep medicine contain a substantial mix of well-established findings, working hypotheses, contested claims, and outright misinformation in lay-media circulation. The master's-level posture toward this landscape is to hold the strong findings with appropriate confidence, hold the contested claims with appropriate calibration, hold the weak claims with appropriate skepticism, and never claim more than the underlying evidence supports.

The strong findings include: CBT-I as first-line treatment for chronic insomnia; CPAP as first-line treatment for moderate-to-severe OSA; the developmental adolescent circadian phase delay and the resulting case for delayed school start times; the Baglioni framework that insomnia is a prospective predictor of incident depression; the high rate of RBD conversion to α-synucleinopathy in longitudinal cohort; the glymphatic clearance framework as a productive translational direction. These can be held with substantial confidence in the graduate-trained practitioner's engagement.

The contested or unresolved territory includes: the specific magnitude and clinical translation of the sleep-cognitive-decline relationship; the optimal sleep duration for population-level health (with cohort studies suggesting U-shaped relationships and the optimum varying across outcomes and populations); the magnitude and translation of the IARC night shift carcinogenicity; the broader translational implications of the Aβ-sleep bidirectional framework. These deserve appropriate calibrated engagement — taking the evidence seriously while recognizing the genuine unresolved questions.

The weak or unsupported territory includes: most "biohacking" sleep claims (precise polyphasic schedules, specific supplement combinations marketed as sleep optimizers, consumer-tracker-derived sleep optimization frameworks beyond trend-level tracking); the precision-claim form of consumer wearable sleep-stage measurement; many of the supplement-for-sleep marketing claims; the broader optimization-of-sleep-architecture frameworks that outrun the underlying evidence. The graduate-trained practitioner engages with patients who reference these claims with the appropriate framing: the underlying research is limited, the marketing has outpaced the evidence, and the population-level effects of these practices are largely unknown.

Closing the Chapter: Coach Sleep's Position at Master's

Coach Sleep at Master's has held to the same position the Cat has held across every prior tier: Consolidation. Sleep is the nightly temporal medium in which every other system's adaptations consolidate — memory consolidation in the brain, glymphatic clearance of metabolic byproducts, restoration of immune function, hormonal cycling, metabolic recovery from the day's activity, the offline reorganization that the waking brain cannot perform on itself. At Master's the Consolidation position deepens at clinical translational depth. We have walked through what clinical sleep medicine actually does (with appropriate humility about implementation gaps), how circadian medicine has translated into clinical practice (with specific precision-medicine successes like tasimelteon and broader translational works-in-progress), what population sleep looks like (with appropriate engagement with the chronic-short-sleep epidemic and the IARC night shift question), and where sleep meets aging and neurodegeneration (with the integrated sleep-inflammation-cognition-mood territory at active research stage).

The integrator ontology — ten positions through which the nine Coaches and their integrative work are organized — holds at Master's as it did at Bachelor's and Associates. The Cat is the Consolidation position. The other eight Coaches hold their own positions at Master's depth, and the Master's-level integrative chapter at the close of this tier will return to the full ontology with the depth that each modality's Master's-level chapter contributes.

You have completed the third of nine Coaches at Master's depth.

The Cat is in no hurry. There will be more.

Lesson Check

1. Describe the de Zambotti 2019 framework on consumer wearable validity. What is the contemporary picture of wearable accuracy for total sleep time, sleep stages, and clinical sleep disorder detection? What is "orthosomnia" and how does it illustrate the broader translational challenge?
2. Summarize the Van Dongen 2003 chronic partial sleep deprivation paradigm. What is the principal finding on cumulative cognitive impairment, and what is the subjective-objective dissociation that complicates self-assessment of impairment?
3. Apply the five-point framework to two of the following claims: "athletes need 10 hours," "polyphasic sleep allows function on 2–4 hours," "consumer wearables accurately measure sleep stages," "magnesium supplementation improves sleep." For each, describe what the framework reveals about the appropriate calibrated engagement.
4. Articulate the publication-bias picture in sleep medicine clinical trials. What are two specific structural features of sleep medicine that complicate evaluation of the published literature?
5. Describe the master's-level posture toward sleep claims at the integrative level. Identify one finding you would hold with substantial confidence, one finding you would hold with appropriate calibration, and one claim you would hold with appropriate skepticism.

---

End-of-Chapter Activity: Methodological Scan-Read of a Published Sleep Medicine Paper

Select a recently published clinical sleep medicine or circadian medicine paper in a peer-reviewed journal (any of Sleep, Journal of Clinical Sleep Medicine, Sleep Medicine, American Journal of Respiratory and Critical Care Medicine, JAMA Internal Medicine, Annals of Internal Medicine, Lancet Respiratory Medicine, Neurology, or comparable). The paper should be one you have not previously encountered and should fall into one of the categories represented in this chapter: a clinical trial of an insomnia, OSA, or narcolepsy intervention; a circadian medicine application study; a sleep epidemiology paper; a sleep-and-neurodegeneration translational study; or a sleep-research-methods methodology paper.

Complete the following structured analysis in writing:

1. Design (one paragraph). Identify the study design and the principal methodological apparatus. For a clinical trial: design type, randomization, blinding, comparator, registration. For an observational study: cohort versus case-control versus cross-sectional, exposure measurement, outcome measurement, statistical adjustment. For a measurement study: validation framework against gold standard, sample characteristics, statistical analysis approach.

2. Population (one paragraph). Describe the enrolled population, inclusion and exclusion criteria, and the implications for external validity. Sleep medicine populations are heterogeneous; identify whether the finding generalizes to broader clinical or population contexts.

3. Intervention or Exposure (one paragraph). Describe the intervention or exposure at the level of operational delivery — what was the dose, duration, schedule. For sleep-specific interventions, characterize whether the protocol could be implemented in real-world clinical practice or whether it requires research-context resources.

4. Outcomes (one paragraph). Identify the prespecified primary outcome and key secondary outcomes. Distinguish subjective outcomes (sleep quality scales, sleep diaries) from objective outcomes (PSG-derived metrics, actigraphy, biomarkers). Compare the prespecified analysis plan with what was reported.

5. Findings (one paragraph). Report the primary outcome result in appropriate effect-size terms. For sleep studies, this typically requires consideration of both statistical significance and clinical meaningfulness — a statistically significant 5-minute improvement in sleep onset latency may or may not be clinically meaningful depending on context.

6. Evaluation (one paragraph). Apply the five-point framework. For sleep medicine studies, explicitly address: the measurement validity (PSG versus actigraphy versus wearable versus self-report); the blinding question (sleep interventions are frequently un-blinded, affecting outcome interpretation); the industry-sponsorship question for pharmacological studies; the implementation feasibility for real-world clinical translation. Conclude with your assessment of how the findings should inform clinical practice, research direction, and individual decision-making.

Length target: 1,500–2,000 words. Cite the paper in full with DOI. Submit as a graduate seminar paper format with references for any additional sources cited.

Repeat the activity weekly during the chapter cycle: one paper in each of the major sleep medicine domains (an insomnia clinical trial; an OSA-treatment study; a circadian medicine application; a sleep epidemiology paper; a sleep-and-aging or sleep-and-disease translational study).

---

Vocabulary Review

Alphabetized terms across all five lessons:

---

Chapter Quiz

Multiple Choice (10 questions, 4 options each)

1. The Spielman 3P model directs treatment of chronic insomnia primarily toward:

A. The predisposing factors, which are the trait-level vulnerability B. The precipitating events, which are the acute stressors that initiated the insomnia C. The perpetuating factors, which are the behavioral and cognitive responses that maintain the insomnia after the precipitant resolves D. Sleep hygiene education exclusively

2. Cognitive Behavioral Therapy for Insomnia (CBT-I) is recommended as first-line treatment for chronic insomnia by:

A. Only the American Academy of Sleep Medicine B. The American Academy of Sleep Medicine, the American College of Physicians, the European Sleep Research Society, and the VA/DoD — across major sleep medicine professional society guidelines C. Only outside the United States D. As second-line treatment after Z-drug pharmacotherapy

3. The dual orexin receptor antagonist class (suvorexant, lemborexant, daridorexant) is mechanistically significant because:

A. It binds the same GABA-A receptor site as Z-drugs with higher selectivity B. It promotes sleep by reducing wake-promoting orexin signaling rather than enhancing GABA-mediated inhibition, representing the first mechanistically novel insomnia drug class since the benzodiazepines C. It produces immediate sleep onset with no daytime carryover D. It can be administered intravenously for rapid effect

4. The benzodiazepine-opioid co-prescribing risk produces increased respiratory depression because:

A. Benzodiazepines and opioids both bind μ-opioid receptors B. The combination is super-additive at clinically relevant doses, with both classes inhibiting respiratory control centers through distinct mechanisms — benzodiazepine GABAergic enhancement and opioid effects at brainstem respiratory generators C. Benzodiazepines block opioid metabolism D. The risk is only theoretical and has not been demonstrated clinically

5. Tasimelteon is FDA-approved specifically for:

A. Sleep-onset insomnia in adults B. Non-24-hour sleep-wake disorder, occurring principally in totally blind individuals C. REM sleep behavior disorder D. Shift work disorder

6. The Wahlstrom and AAP 2014 framework on school start times recommends that middle and high schools start no earlier than:

A. 7:30 AM B. 8:00 AM C. 8:30 AM D. 9:00 AM

7. The Baglioni et al. 2011 systematic review and meta-analysis demonstrated that:

A. Depression is the principal cause of insomnia B. Insomnia at baseline prospectively predicts incident major depressive disorder with relative risks of approximately 2.0–2.6 across studies C. CBT-I is ineffective for comorbid depression D. Sleep duration is unrelated to mental health outcomes

8. The Lucey et al. 2022 Annals of Neurology finding demonstrated that:

A. Reduced slow-wave activity is associated with elevated CSF tau and longitudinal cognitive decline in preclinical AD B. Total sleep duration is the strongest predictor of AD progression C. Sleep medications prevent AD D. RBD does not predict α-synucleinopathy

9. The Postuma et al. 2019 longitudinal cohort of idiopathic RBD patients found cumulative conversion to defined α-synucleinopathy at 14-year follow-up of approximately:

A. 10% B. 25% C. 50% D. 75–80%

10. The de Zambotti 2019 framework on consumer sleep wearable validity demonstrates that:

A. Consumer wearables are interchangeable with PSG for clinical sleep evaluation B. Total sleep time estimation by consumer wearables is reasonable at population level; sleep-stage estimation is systematically biased; clinical sleep disorder detection is limited C. Consumer wearables are completely inaccurate for any sleep measurement D. Consumer wearables produce higher accuracy than PSG

Short Answer (5 questions)

11. Describe the Spielman 3P model of insomnia. Explain how the model translates into the operational components of CBT-I, identifying which CBT-I components target which perpetuating factors specifically.

12. A patient is preparing for an eastward 8-hour trip (e.g., U.S. East Coast to Western Europe). Apply the Eastman-Burgess framework to design a chronotherapy approach. Describe the direction of required phase shift, the pre-trip preparation, the destination-side light exposure and avoidance schedule, and the adjunctive melatonin timing.

13. The benzodiazepine-opioid co-prescribing risk produced FDA boxed warnings in 2016. Describe the pharmacological mechanism at receptor and respiratory-control depth (drawing on Breath Bachelor's Lesson 1 material as appropriate), identify the clinical-population contexts in which the risk is most acute, and articulate the appropriate role of master's-level adjacent practitioners in supporting safer co-prescription practice.

14. Trace the glymphatic-AD framework from the Iliff 2012 / Xie 2013 foundational work through the Lucey 2022 slow-wave-AD finding. Identify the strongest pieces of supporting evidence, the principal methodological constraints that should be acknowledged, and the translational implications for clinical practice and research direction.

15. Apply the five-point framework to evaluate the following hypothetical consumer claim: "Our advanced sleep wearable uses AI to optimize your sleep stages and improve your deep sleep by 30%." For each of the five framework points (design, population, measurement, effect size, replication), describe what the framework reveals about the appropriate calibrated engagement with the claim.

---

Instructor's Guide

Pacing Recommendations

This chapter is content-dense and clinically substantial. The estimated 22–26 class periods allow each lesson adequate depth. Suggested pacing for a 14-week graduate seminar:

• Weeks 1–3 (Lesson 1): Clinical Sleep Medicine and Treatment Landscape. Pair with Spielman 1986 (foundational anchor), Morin 1999 JAMA CBT-I RCT, Trauer 2015 Annals CBT-I meta-analysis, and Sun 2017 BMJ BZ-opioid co-prescribing as primary readings. Consider clinical guest faculty from sleep medicine and behavioral sleep medicine.
• Weeks 4–5 (Lesson 2): Circadian Medicine. Pair with Eastman/Burgess jet-lag protocol papers, Rosenthal SAD foundational work and Golden 2005 meta-analysis, tasimelteon non-24h RCT as primary readings.
• Weeks 6–8 (Lesson 3): Sleep Epidemiology and Public Health. Pair with CDC BRFSS sleep duration analyses, IARC 2007/2019 reports, Wahlstrom school-start-time papers, AAP 2014 policy statement, Baglioni 2011 meta-analysis as primary readings.
• Weeks 9–10 (Lesson 4): Sleep, Aging, and Neurodegeneration. Pair with Iliff 2012 / Xie 2013 glymphatic papers, Lucey 2022 Annals of Neurology, Holtzman Aβ-sleep papers, Postuma 2019 Brain RBD cohort as primary readings.
• Weeks 11–13 (Lesson 5): Research Methods at Translational Depth. Pair with de Zambotti 2019 wearable review, Van Dongen 2003 Sleep, sleep medicine meta-analytic methodology papers as primary readings.
• Week 14: Chapter integration, end-of-chapter activity submissions, oral seminar presentations of selected paper scan-reads.

A condensed version (6–8 week module) groups lessons at the cost of depth.

Lesson Check Answers

Lesson 1.

1. The 3P model holds that chronic insomnia is maintained by perpetuating factors (behavioral and cognitive responses) more than by the original precipitant. The precipitant is rarely directly treatable; the predisposing factors are largely trait-level; the perpetuating factors are behaviorally modifiable. CBT-I targets the perpetuating factors directly (sleep restriction addresses the extension-of-time-in-bed factor; stimulus control addresses weakened bed-sleep association; cognitive therapy addresses worry-and-performance-anxiety cognitions), which is why the model drives contemporary treatment design.
2. Five CBT-I components: Sleep Restriction Therapy, Stimulus Control, Cognitive Therapy, Sleep Hygiene Education, Relaxation Training. SRT and Stimulus Control are the strongest standalone components with substantial evidence as effective monotherapy in some trials. Sleep Hygiene Education is the weakest standalone component, insufficient as monotherapy.
3. Z-drugs: GABA-A receptor positive allosteric modulators with relative α1 selectivity; principal effect on sleep onset and maintenance; side-effect profile includes complex sleep behaviors, morning sedation, dependence and rebound insomnia; controlled-substance scheduled (Schedule IV). DORAs: orexin receptor antagonists (OX1R and OX2R); principal effect on sleep onset and maintenance; side-effect profile includes morning somnolence, abnormal dreams, sleep paralysis; less complex-sleep-behavior risk than Z-drugs; also Schedule IV but with apparently lower abuse/dependence risk in available evidence.
4. BZ-opioid co-prescribing risk per FDA 2016 boxed warnings: combined respiratory depression at rates significantly elevated over either class alone, with super-additive (not merely additive) interaction at clinically relevant doses. Mechanism: benzodiazepines enhance GABAergic inhibition at GABA-A receptors throughout CNS including respiratory control centers; opioids inhibit respiratory drive at pre-Bötzinger complex (rhythm generator) and parabrachial-Kölliker-Fuse complex (chemoreceptor-mediated drive). Acute risk: chronic opioid therapy patients, opioid use disorder patients on methadone or buprenorphine, palliative care patients, and any clinical context with concurrent opioid and benzodiazepine prescription.
5. Eckert phenotyping applied: Pcrit (anatomical collapsibility) → CPAP, MAD, upper airway surgery, weight loss. Loop gain (ventilatory control instability) → supplemental oxygen, acetazolamide. Low arousal threshold → sedatives that raise arousal threshold without further suppressing respiratory drive. Muscle responsiveness → hypoglossal nerve stimulation, emerging pharmacological approaches.

Lesson 2.

1. Phase-advanced light protocols (Eastman): partial circadian phase shifts in shift workers with moderate effect; complete adaptation rare given inevitable daytime light and weekend social rhythms. Wake-promoting medications (modafinil, armodafinil): address wakefulness during shift without addressing underlying circadian misalignment. Melatonin: promotes post-shift daytime sleep onset with modest objective effect on sleep parameters. Scheduling design: forward-rotating with extended periods over backward-rotating or rapid-rotating; affects shift-work tolerance independent of individual intervention.
2. Eastward 6-hour shift requires phase advance (body needs to shift earlier). Pre-trip: begin advancing the home phase by approximately 1 hour per day over 3 days before travel using morning bright light exposure. Destination: morning bright light exposure for 30–60 minutes within the first hour after target wake time; evening light avoidance for 2–3 hours before target sleep time. Adjunctive melatonin: 0.5–3 mg in the late afternoon to early evening (the melatonin-PRC phase-advance window — approximately 5–7 hours before target sleep time). Continue protocol for several days at destination until entrained.
3. Non-24-hour sleep-wake disorder: circadian rhythm disorder in which endogenous period differs sufficiently from 24 hours that entrainment fails; occurs principally in totally blind individuals without functional retinal photoreception. Tasimelteon FDA-approved for this indication in 2014. Represents precision-medicine success because: defined patient population (mechanistically identifiable), mechanistically-grounded intervention (MT1/MT2 agonism substituting for absent light input), clinical-translation evidence (entrainment in approximately 20% of treated patients with clinically meaningful improvements in nighttime sleep and daytime alertness).
4. Standard SAD protocol: 10,000 lux of broad-spectrum white light for 30 minutes daily; morning timing shortly after waking; treatment started in late autumn and continued through winter months. Principal contraindication requiring clinical assessment before initiation: bipolar diathesis, given risk of mood activation precipitating manic or hypomanic episode in patients with bipolar disorder or bipolar-spectrum vulnerability.
5. DSPD chronotherapy four interventions: (a) scheduled morning bright light (10,000 lux for 30 minutes within first 30–60 minutes after target wake time); (b) evening light avoidance (reducing blue-light-rich evening illumination 2–3 hours before target sleep time); (c) evening low-dose melatonin (0.3–0.5 mg, 5–7 hours before target sleep time); (d) scheduled sleep advancement (gradual advance of bedtime by 15–30 minutes every few days). Practical limits in adolescents: sustained protocol adherence across school and weekend days (social-jet-lag erosion), practical difficulty of morning bright light in winter mornings before sunrise, family-system implementation challenges.

Lesson 3.

1. Chronic short sleep epidemic: approximately one-third of U.S. adults report sleeping fewer than 7 hours per night per CDC BRFSS. Demographic correlates: Black and Hispanic adults shorter than non-Hispanic white; lower-income shorter than higher-income; shift-work occupations (healthcare, transportation, manufacturing, hospitality, public safety) shorter than typical-schedule occupations; urban areas with higher noise and light pollution shorter than rural. Sleep health disparities partially attributable to structural and environmental determinants beyond individual choice.
2. IARC Group 2A: night shift work probably carcinogenic to humans. Principal cancer sites of concern: breast cancer (Nurses' Health Study evidence), prostate cancer. Methodological constraints: human epidemiological evidence is limited and has been reassessed (Million Women Study null, NHS-II updated exposure assessment attenuated); animal mechanistic evidence is substantial. Policy translation: partial — Denmark compensation framework for breast cancer in night shift workers, some European jurisdictions similar, most U.S. and global jurisdictions no corresponding policy; structural workplace reform has not occurred at the scale a Group 2A classification typically catalyzes.
3. Wahlstrom Edina/Minneapolis findings: consistent improvement in attendance, decreased tardiness, increased graduation rates, improved standardized test scores, decreased self-reported sleep disturbance, decreased adolescent depression and substance use after high school start time delay. AAP 2014 recommendation: middle and high schools start no earlier than 8:30 AM. Real-world outcomes in implementing districts: broadly favorable on educational, mental health, and traffic-safety outcomes; California SB 328 statewide implementation as principal natural-experiment opportunity. Principal implementation challenge: after-school schedule cascade effects (athletics, employment, family caregiving), transportation logistics, elementary school timing cascades.
4. Baglioni 2011: prospective epidemiological studies consistently demonstrate insomnia at baseline predicts incident MDD over follow-up with relative risks 2.0–2.6 across studies. Shaped contemporary comorbid-insomnia-depression treatment by demonstrating that addressing insomnia as a target in its own right (rather than expecting depression treatment to resolve comorbid insomnia) produces better outcomes; led to studies like Manber 2008 showing CBT-I + antidepressant superior to antidepressant alone in comorbid populations.
5. Drowsy driving: AAA Foundation estimates approximately one in six fatal crashes involves drowsy driver; one in three U.S. drivers report drowsy driving in prior month; one in twenty report falling asleep at wheel. Williamson-Feyer equivalence: 17–19 hours of sustained wakefulness produces driving impairment equivalent to BAC 0.05–0.08%; 24 hours equivalent to legally intoxicated driving. Elevated-risk populations: shift workers, commercial drivers, patients with untreated OSA, adolescents, patients on sedating medications.

Lesson 4.

1. Lifespan sleep architecture changes: substantial decline in N3/slow-wave sleep (~15–20% young adult → 5–10% age 60–70 → <5% age 80+); increased sleep fragmentation with more awakenings and arousals; advanced sleep phase (earlier bedtimes and wake times by 1–2 hours from young to older adulthood); relative preservation of REM proportion despite absolute decreases. Clinical implications: framing of "I wake up at 4 AM and can't sleep" as developmental change requiring assessment for clinical contributors; cautious sleep medication prescribing in older adults (reduced clearance, increased sensitivity to GABA-A modulation, fall risk, Beers Criteria); recognition that older-adult sleep disturbance is a clinical signal warranting systematic assessment.
2. Glymphatic framework: Iliff 2012 paper established perivascular CSF clearance pathway with peri-arterial entry, AQP4-mediated exchange, peri-venous drainage. Xie 2013 demonstrated substantially elevated glymphatic activity during sleep (interstitial space ↑60%, Aβ clearance ~doubles). Strong supporting evidence: animal mechanistic work, human acute sleep-deprivation increases in CSF Aβ, the Lucey 2022 SWA-tau-cognitive-decline finding. Methodological constraints: original work rodent-based with translation difficulty; some biophysical-plausibility challenges to proposed flow magnitudes (Smith/Verkman 2018); specific quantitative claims not fully settled.
3. Aβ-sleep bidirectional: Holtzman mouse-model work (2009 Science) — interstitial Aβ rises during waking and falls during sleep in orexin-dependent manner; chronic sleep deprivation accelerates plaque formation; orexin antagonism reduces Aβ. Human acute findings: one night of sleep deprivation increases CSF Aβ42 (Lucey 2018); slow-wave-sleep disruption increases CSF Aβ42 even without total sleep time change (Ju 2017). Cross-sectional epidemiology: shorter self-reported sleep duration associated with elevated amyloid burden on PET in cognitively normal older adults (Spira 2013). Causal-inference challenges: bidirectionality (sleep ↔ Aβ both directions), reverse causation in observational studies, methodological complexity of disentangling direction at human population scale.
4. Postuma 2019 Brain: 1,280 patients with polysomnography-confirmed idiopathic RBD followed across multiple international centers average 4.6 years. Cumulative phenoconversion to defined α-synucleinopathy approximately 6% per year; 14-year cumulative conversion approaching 75–80%. Clinical implications: RBD diagnosis carries substantial prognostic weight requiring appropriate clinical communication; RBD population is the natural target for neuroprotective-intervention trials; early detection has clinical-counseling implications and may have intervention implications as disease-modifying treatments develop.
5. Sleep-inflammation-cognition-mood integrated framework: chronic sleep disruption produces low-grade systemic inflammation through HPA dysregulation, sympathetic activation, altered cytokine signaling; inflammatory state contributes to depression, cognitive decline, and cardiometabolic disease. Principal methodological challenge: the many bidirectional relationships involved (sleep ↔ inflammation, inflammation ↔ depression, depression ↔ sleep, depression ↔ cognition, sleep ↔ cognition, all simultaneously) complicate causal inference; the integrated benefit of any single intervention cannot be assumed from the framework alone.

Lesson 5.

1. de Zambotti 2019 framework: consumer wearable total-sleep-time accuracy reasonable at population level (within 15–30 minutes of PSG in healthy adults), with substantial individual-level error. Sleep-stage estimation systematically biased — over-estimating deep sleep, under-estimating REM, stage-specific error patterns not stable across patients or nights. Clinical sleep disorder detection is limited — devices do not reliably detect OSA or other clinical conditions. Orthosomnia: patients developing or worsening insomnia in response to anxiety about consumer-tracker sleep data; illustrates broader translational principle that consumer health-tracking can produce real harm when generating clinical concern beyond what underlying measurement supports.
2. Van Dongen 2003: 14-night chronic restriction protocol at 4, 6, or 8 hours in bed. Principal finding: cognitive performance decrements accumulated across days at 4- and 6-hour restriction levels, with 4-hour group reaching impairment equivalent to total sleep deprivation by day 14 and 6-hour group equivalent to 24-hour total sleep deprivation by day 14. Subjective-objective dissociation: subjective sleepiness ratings did not track with objective performance — participants progressively under-estimated their impairment. Clinical and population implication: chronic short sleep produces functional impairment not subjectively recognized, with consequences for shift workers, students, and broader chronic-short-sleep populations.
3. Sample answers — (a) "Athletes need 10 hours": within-subjects pre-post design in sleep-restricted collegiate male basketball players; finding meaningful in this specific population; "10 hours" reflects protocol design rather than physiological requirement; replication mixed across sports. (b) "Polyphasic sleep allows 2–4 hours function": no adequate clinical trials; available evidence does not support claim; adjacent sleep deprivation research directly contradicts; should be held with substantial skepticism. (c) "Consumer wearables accurately measure sleep stages": systematically biased per de Zambotti 2019; appropriate use is trend-level total sleep time; stage-level claims overstate what evidence supports. (d) "Magnesium improves sleep": small RCT evidence base; modest subjective effects; marketing outruns research; reasonable safety profile but evidence-supported framing requires appropriate calibration.
4. Sleep medicine publication bias structural features: subjective outcomes dominate (sleep quality scales, sleep diaries) with expectancy and unblinding vulnerabilities; industry sponsorship concentration in sleep-medication trials with associated bias structure (Bes-Rastrollo framework); behavioral intervention trials predominantly academic with positive-result publication skew; the contemporary trial-registration environment has improved the situation prospectively without correcting the historical literature on which much guidance rests.
5. Calibrated master's-level posture examples — substantial confidence: CBT-I as first-line for chronic insomnia; CPAP for moderate-to-severe OSA; adolescent circadian phase delay supporting delayed school start times; insomnia as prospective depression risk factor (Baglioni); high RBD-to-α-synucleinopathy conversion rate (Postuma). Appropriate calibration: glymphatic AD framework (substantial but with methodological constraints to acknowledge); IARC night shift carcinogenicity (mechanistic strong, human epidemiology constrained); sleep-cognitive-decline framework. Appropriate skepticism: polyphasic sleep claims; precision-claim form of consumer wearable stage measurement; most "biohacking" supplement-and-product optimization claims.

Quiz Answer Key

Multiple Choice:

1. C — Perpetuating factors. The model's clinical translation directs treatment toward the behavioral and cognitive responses that maintain insomnia after the precipitant resolves.
2. B — Across major sleep medicine professional society guidelines. AASM, ACP, ESRS, and VA/DoD all recommend CBT-I as first-line treatment for chronic insomnia.
3. B — Reduces wake-promoting orexin signaling; first mechanistically novel insomnia drug class since benzodiazepines. The mechanistic distinction from GABA-A modulation is the structural significance.
4. B — Super-additive at clinically relevant doses through distinct respiratory-control mechanisms. The pharmacological interaction produces respiratory depression exceeding the algebraic sum of individual effects.
5. B — Non-24-hour sleep-wake disorder in totally blind individuals. The precision-medicine indication where the absence of light input to the SCN means the endogenous circadian system runs at its natural period.
6. C — 8:30 AM. The AAP 2014 recommendation is based on adolescent developmental sleep biology and substantial educational/health/safety evidence.
7. B — Insomnia at baseline prospectively predicts incident MDD with relative risks 2.0–2.6. The bidirectional relationship has subsequently been confirmed in meta-analytic updates.
8. A — Reduced slow-wave activity associated with elevated CSF tau and longitudinal cognitive decline in preclinical AD. The framework supports the hypothesis that sleep architecture changes are part of early AD pathophysiology rather than merely downstream of established disease.
9. D — 75–80% cumulative conversion at 14-year follow-up. The conversion rate has substantial clinical implications for early detection and for prognostic counseling.
10. B — Reasonable total sleep time accuracy at population level; systematic stage-estimation bias; limited clinical sleep disorder detection. The framework supports trend-level use rather than substitution for clinical evaluation.

Short Answer: See lesson check answers and chapter content. Grade on the dimensions of: methodological accuracy, framework integration, recognition of what evidence supports and does not support, and graduate-level disposition toward unresolved questions.

Discussion Prompts

1. CBT-I has been the recommended first-line treatment for chronic insomnia for over a decade in major guidelines, yet sleep-medication prescription remains substantially more common in U.S. primary care than CBT-I referral. What structural, economic, training-pipeline, and patient-side factors explain the guideline-versus-practice gap, and what would be required to close it?
2. The dual orexin receptor antagonist class is the most mechanistically novel sleep-pharmacology innovation in decades. Where should the class sit in clinical practice in 5 years? What evidence would justify expanded use, and what evidence would limit it?
3. The psychedelic-assisted therapy direction (Coach Brain Master's Lesson 1) has produced substantial trial-level effects; the precision-medicine inflammatory-depression direction (Coach Brain Master's Lesson 4) has produced biomarker-stratified intervention frameworks. Where does sleep-targeted intervention for mood and cognition fit in this broader landscape of mechanism-targeted psychiatric medicine?
4. The IARC night shift Group 2A classification has been on the books for nearly two decades without producing structural workplace reform. Discuss the gap between scientific evidence and population-level policy change. What would catalyze structural workplace intervention in night shift work?
5. The school-start-time research is among the cleanest translational stories in adolescent public health, yet implementation has been uneven across U.S. states. What does the California SB 328 implementation experience suggest about translating well-established research into population-level policy?
6. The glymphatic clearance framework has produced substantial research excitement and lay-press coverage. Apply the master's-level calibrated-engagement framework. What should we hold with substantial confidence, what should we hold with appropriate calibration, and what should we hold with appropriate skepticism in the framework as it stands in 2026?
7. RBD is the strongest available prodromal marker for α-synucleinopathies. Yet no approved disease-modifying intervention exists. Discuss the clinical-communication challenges of delivering an RBD diagnosis. How should clinical practice manage the gap between the prognostic information and the limited actionable intervention?
8. Consumer sleep wearables have proliferated substantially over the past decade. Discuss the regulatory, clinical-practice, and public-health implications of this technology. How should the field engage with the consumer-tracker industry: as ally, as adversary, as both, or as something else?

Common Student Questions

1. "Should I recommend CBT-I to my clinical patients with insomnia?" Yes, if you are trained and licensed to deliver it (or to refer). CBT-I is first-line per all major guidelines. If access is limited in your practice setting, the digital CBT-I platforms (Sleepio and others) have substantial RCT evidence and can extend access; the AASM and adjacent professional societies maintain referral directories of trained behavioral sleep medicine clinicians.

2. "What should I tell patients about their consumer sleep tracker data?" Use it for trend-level information at the week-to-week and month-to-month level — bedtime regularity, approximate total sleep time, sleep-time-of-night patterns. Do not interpret sleep-stage data as comparable to PSG. If the patient is concerned about a specific sleep disorder, refer for clinical evaluation rather than relying on the tracker.

3. "How do I discuss the BZ-opioid co-prescribing risk with patients?" Within scope of practice — as a recognition of clinical risk that the prescribing clinician(s) and the multidisciplinary team should be addressing. The actual prescribing decision is the prescribing clinician's; the master's-level adjacent practitioner who recognizes the risk and supports the patient's engagement with their clinical team operates appropriately.

4. "What is the best sleep duration for adults?" The professional society consensus (NSF, AASM/SRS) recommends 7 or more hours nightly for most adults. Individual optimal duration varies; some adults function well at the lower end of the recommended range and some require longer. The clinical guidance is: subjective non-restorative sleep, daytime sleepiness, or chronic short sleep below the recommended range warrants clinical evaluation rather than acceptance as "I just need less sleep."

5. "How should I think about melatonin supplementation?" Distinguish between (a) low-dose melatonin (0.3–0.5 mg) for circadian phase-shifting in defined contexts (jet lag, DSPD, shift work) and (b) higher-dose melatonin (3–10 mg) for sleep-onset insomnia in healthy adults. The evidence for (a) is moderate within the appropriate phase-of-PRC timing; the evidence for (b) is weaker than the OTC marketing suggests. The Erland-Saxena product-quality findings should inform clinical conversation about specific brand selection.

6. "What about modafinil for someone with chronic short sleep who isn't sleepy enough for narcolepsy diagnosis?" Modafinil is FDA-approved for excessive daytime sleepiness in narcolepsy, OSA-related residual sleepiness, and shift work disorder. Off-label use for chronic short sleep without these defined conditions is widespread but does not have a strong evidence base; the appropriate framing is that chronic short sleep is addressable by addressing the underlying short-sleep cause rather than by adding wakefulness pharmacology.

7. "My patient has been on chronic Z-drug use for years. How should I think about deprescribing?" This is a deprescribing question, like the chronic benzodiazepine deprescribing covered in Coach Brain Master's Lesson 1. The clinical guidance favors slow tapering with concurrent CBT-I delivery, given the protracted withdrawal and rebound-insomnia risks. The actual deprescribing is conducted by the prescribing clinician; master's-level adjacent practitioners in behavioral medicine support the process and may deliver the CBT-I component.

8. "What about cannabis or CBD for sleep?" The evidence base is limited and the contemporary translational picture is unsettled. THC may reduce sleep onset latency acutely but disrupts sleep architecture (REM suppression in particular); the chronic effects and the cannabis-use-disorder context complicate the picture. CBD-for-sleep evidence is thin; some specific indications (Lennox-Gastaut, Dravet syndromes for cannabidiol epilepsy treatment) have FDA approval but those are distinct from general-sleep applications. Patient conversations should distinguish the regulatory, evidence, and clinical-context picture rather than treating cannabis/CBD as evidence-supported sleep interventions.

Cohort/Advisor Communication Template

Master's-level study in clinical sleep medicine involves substantial engagement with clinical content (severe insomnia, the BZ-opioid risk, sleep-mental health bidirectional relationship, sleep-and-neurodegeneration) that may be psychologically demanding. Programs should consider proactive cohort and advisor support around the chapter.

Suggested cohort/advisor email template:

Subject: Chapter 1 of the Master's Coach Sleep curriculum — note on clinical content and self-care

Dear [cohort/advisee],

The first chapter of the Master's Coach Sleep curriculum covers clinical sleep medicine practice, circadian medicine clinical applications, sleep epidemiology and public health, sleep and aging and neurodegenerative disease, and sleep research methods at translational depth. The chapter engages substantively with clinical content including treatment-resistant insomnia, the benzodiazepine-opioid co-prescribing risk, the sleep-mental health bidirectional relationship, and the prognostic implications of REM behavior disorder.

The chapter's framing throughout is recognition, clinical reasoning, and methodological depth — never diagnostic prescription. The work of clinical sleep medicine practice remains the work of trained sleep medicine clinicians, behavioral sleep medicine specialists, and the multidisciplinary teams within which they operate. If anything in your engagement with the chapter — or with your broader graduate training — surfaces concerns about your own wellbeing or that of someone close to you, please be in touch.

Resources at the chapter's close include the 988 Suicide & Crisis Lifeline (call or text 988), the Crisis Text Line (text HOME to 741741), the SAMHSA National Helpline (1-800-662-4357), and the National Alliance for Eating Disorders helpline (866-662-1235). Your program's counseling and student wellness resources are available to you.

Warmly, [program director / faculty advisor]

---

Illustration Briefs

Lesson 1 illustration: Clinical Sleep Medicine and the Treatment Landscape

• Placement: end of Lesson 1, after "What This Lesson Built"
• Scene: graduate-seminar table with a wall behind showing the Spielman 3P framework as a triangle (predisposing/precipitating/perpetuating), the CBT-I component cluster (SRT, stimulus control, cognitive therapy, hygiene, relaxation), the medication landscape (Z-drugs, DORAs, ramelteon, trazodone) with receptor-target labels, the CPAP and MAD and HGNS schematic, the Eckert phenotyping quadrant.
• Coach involvement: Coach Sleep (the Cat) calm, observing the full picture.
• Mood: graduate seminar, integrative depth, no theatricality.
• Key elements: 3P triangle; CBT-I components; medication classes; OSA treatment schematic; Eckert phenotyping.
• Aspect ratio: 16:9 web, 4:3 print.

Lesson 2 illustration: Circadian Medicine Clinical Applications

• Placement: end of Lesson 2, after "What This Lesson Built"
• Scene: graduate-seminar table with wall behind showing the integrated circadian medicine landscape — a PRC plotted with light and melatonin shift directions; the Eastman jet-lag protocol diagram for eastward and westward travel; the bright-light-therapy clinical setup (10,000 lux box, morning timing); the tasimelteon precision-medicine indication (non-24h in blind individuals); the chrononutrition meal-timing diagram.
• Coach involvement: Coach Sleep observing the integrated picture.
• Mood: clinical translational, integrative, no theatricality.
• Key elements: PRC; jet-lag protocols; light therapy setup; tasimelteon indication; chrononutrition.
• Aspect ratio: 16:9 web, 4:3 print.

Lesson 3 illustration: Sleep Epidemiology and Public Health

• Placement: end of Lesson 3, after "What This Lesson Built"
• Scene: graduate-seminar table with wall behind showing the public health landscape — U.S. map with state-level sleep-duration BRFSS data; adolescent circadian phase delay diagram alongside school start times; AAA Foundation drowsy driving prevalence and crash data; IARC Group 2A classification and sleep-inflammation-mood triangle.
• Coach involvement: Coach Sleep clear-eyed, observing population realities.
• Mood: clear-eyed observation, no theatricality.
• Key elements: state-level sleep map; adolescent phase delay; drowsy driving data; IARC classification; sleep-inflammation-mood triangle.
• Aspect ratio: 16:9 web, 4:3 print.

Lesson 4 illustration: Sleep, Aging, and Neurodegenerative Disease

• Placement: end of Lesson 4, after "The Sleep-Inflammation-Cognition-Mood Integration"
• Scene: graduate-seminar table with wall behind showing — lifespan sleep architecture changes (SWS decline, fragmentation increase, phase advance); glymphatic system diagram with peri-arterial CSF entry, AQP4 channels, peri-venous drainage; Aβ-sleep bidirectional cartoon; RBD-to-α-synucleinopathy conversion curve from Postuma 2019; sleep-inflammation-cognition-mood integrated triangle.
• Coach involvement: Coach Sleep integrative, methodologically careful.
• Mood: integrative, methodologically careful, no theatricality.
• Key elements: lifespan architecture; glymphatic system; Aβ-sleep; RBD conversion curve; integrated triangle.
• Aspect ratio: 16:9 web, 4:3 print.

Lesson 5 illustration: Closing the Chapter

• Placement: end of Lesson 5, after "Closing the Chapter"
• Scene: graduate-seminar table with the chapter's principal landmark findings on the board: Spielman 1986 (3P model, foundational anchor), Morin 1999 (CBT-I landmark), Eckert 2013 (OSA phenotyping), Baglioni 2011 (insomnia-depression bidirectional), Lucey 2022 (slow-wave activity in preclinical AD), Postuma 2019 (RBD-α-synucleinopathy conversion), de Zambotti 2019 (wearable validity gap), Van Dongen 2003 (chronic partial restriction).
• Coach involvement: Coach Sleep calm, integrative, the same Cat as in every prior tier, deeper by one level.
• Mood: graduate-seminar conclusion, no theatricality.
• Key elements: landmark-findings board; integrative posture; Cat in closing posture.
• Aspect ratio: 16:9 web, 4:3 print.

---

Crisis and Clinical Support Resources

This chapter engages substantively with clinical sleep medicine content (treatment-resistant insomnia, the benzodiazepine-opioid co-prescribing risk, the sleep-mental health bidirectional relationship, the prognostic implications of REM behavior disorder, drowsy driving as life-safety surface) that may surface professional or personal concerns. The following resources are verified at time of writing. Re-verify before reuse in republished or derivative content.

• 988 Suicide & Crisis Lifeline — Call or text 988. 24/7 free and confidential support for people in distress, including thoughts of suicide and other mental-health crises. Verified operational as of May 2026.
• Crisis Text Line — Text HOME to 741741. 24/7 free crisis text support in the United States, Canada (text HOME to 686868), and the United Kingdom (text SHOUT to 85258).
• SAMHSA National Helpline — 1-800-662-HELP (4357). 24/7 free and confidential treatment referral and information service for mental health and substance use disorders, including support for medication-related concerns and deprescribing pathways. Verified operational as of May 2026.
• National Alliance for Eating Disorders Helpline — (866) 662-1235. Weekdays 9 am–7 pm Eastern. Staffed by licensed therapists, providing referrals to evidence-based eating-disorder treatment.

Note on NEDA: The National Eating Disorders Association helpline (1-800-931-2237) is non-functional and has been since June 2023. Do not reference the NEDA helpline number in any clinical context. Use the National Alliance for Eating Disorders (866-662-1235) as the appropriate eating-disorder-specific resource.

Drowsy driving resources:

• AAA Foundation for Traffic Safety — drowsy driving prevalence, prevention guidance, and educational resources: aaafoundation.org
• National Highway Traffic Safety Administration (NHTSA) — drowsy driving prevention resources: nhtsa.gov
• Federal Motor Carrier Safety Administration (FMCSA) — commercial driver hours-of-service regulations and OSA screening guidance: fmcsa.dot.gov

For clinical and professional resources:

• American Academy of Sleep Medicine (AASM): aasm.org — clinical practice guidelines, board certification, member directory
• Society of Behavioral Sleep Medicine: behavioralsleep.org — CBT-I clinician directory and continuing education
• American Academy of Dental Sleep Medicine: aadsm.org — dental sleep medicine and OSA oral appliance resources
• World Sleep Society: worldsleepsociety.org — international sleep medicine resources

For research methodology resources:

• EQUATOR Network (reporting standards): equator-network.org
• ClinicalTrials.gov (trial registration): clinicaltrials.gov
• Cochrane Library: cochranelibrary.com
• Sleep Research Society: sleepresearchsociety.org

If you are a student, researcher, or practitioner in distress, the resources above are real. The work you are training to do — supporting the sleep and rest of the people you will serve — is meaningful and sustained by sustainable patterns in the people doing it. Pause when you need to. Use the resources. The Cat, and the field, are in no hurry.

---

Citations

1. Spielman, A. J., Caruso, L. S., & Glovinsky, P. B. (1987). A behavioral perspective on insomnia treatment. Psychiatric Clinics of North America, 10(4), 541–553.
2. Perlis, M. L., Giles, D. E., Mendelson, W. B., Bootzin, R. R., & Wyatt, J. K. (1997). Psychophysiological insomnia: the behavioural model and a neurocognitive perspective. Journal of Sleep Research, 6(3), 179–188. DOI: 10.1046/j.1365-2869.1997.00045.x.
3. Bonnet, M. H., & Arand, D. L. (2010). Hyperarousal and insomnia: state of the science. Sleep Medicine Reviews, 14(1), 9–15. DOI: 10.1016/j.smrv.2009.05.002.
4. Edinger, J. D., Wohlgemuth, W. K., Radtke, R. A., Marsh, G. R., & Quillian, R. E. (2001). Cognitive behavioral therapy for treatment of chronic primary insomnia: a randomized controlled trial. JAMA, 285(14), 1856–1864. DOI: 10.1001/jama.285.14.1856.
5. Spielman, A. J., Saskin, P., & Thorpy, M. J. (1987). Treatment of chronic insomnia by restriction of time in bed. Sleep, 10(1), 45–56.
6. Maurer, L. F., Espie, C. A., Omlin, X., et al. (2020). Isolating the role of time in bed restriction in the treatment of insomnia. Sleep, 43(11), zsaa096. DOI: 10.1093/sleep/zsaa096.
7. Bootzin, R. R. (1972). Stimulus control treatment for insomnia. Proceedings of the 80th Annual Convention of the American Psychological Association, 7, 395–396.
8. Harvey, A. G. (2002). A cognitive model of insomnia. Behaviour Research and Therapy, 40(8), 869–893. DOI: 10.1016/s0005-7967(01)00061-4.
9. Irish, L. A., Kline, C. E., Gunn, H. E., Buysse, D. J., & Hall, M. H. (2015). The role of sleep hygiene in promoting public health: a review of empirical evidence. Sleep Medicine Reviews, 22, 23–36. DOI: 10.1016/j.smrv.2014.10.001.
10. Lichstein, K. L. (2017). Behavioral treatments for insomnia: practical implementation. Sleep Medicine Reviews, 36, 1–4. DOI: 10.1016/j.smrv.2017.03.001.
11. Morin, C. M., Colecchi, C., Stone, J., Sood, R., & Brink, D. (1999). Behavioral and pharmacological therapies for late-life insomnia: a randomized controlled trial. JAMA, 281(11), 991–999. DOI: 10.1001/jama.281.11.991.
12. Manber, R., Edinger, J. D., Gress, J. L., San Pedro-Salcedo, M. G., Kuo, T. F., & Kalista, T. (2008). Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. Sleep, 31(4), 489–495. DOI: 10.1093/sleep/31.4.489.
13. Espie, C. A., Kyle, S. D., Williams, C., et al. (2012). A randomized, placebo-controlled trial of online cognitive behavioral therapy for chronic insomnia disorder delivered via an automated media-rich web application. Sleep, 35(6), 769–781. DOI: 10.5665/sleep.1872.
14. Garland, S. N., Carlson, L. E., Stephens, A. J., Antle, M. C., Samuels, C., & Campbell, T. S. (2014). Mindfulness-based stress reduction compared with cognitive behavioral therapy for the treatment of insomnia comorbid with cancer: a randomized, partially blinded, noninferiority trial. Journal of Clinical Oncology, 32(5), 449–457. DOI: 10.1200/JCO.2012.47.7265.
15. Bei, B., Pinnington, D. M., Quin, N., et al. (2023). Improving perinatal sleep via a scalable cognitive behavioural intervention: findings from the SEED randomised controlled trial. Lancet Psychiatry, 10(5), 348–360. DOI: 10.1016/S2215-0366(23)00060-1.
16. Trauer, J. M., Qian, M. Y., Doyle, J. S., Rajaratnam, S. M. W., & Cunnington, D. (2015). Cognitive behavioral therapy for chronic insomnia: a systematic review and meta-analysis. Annals of Internal Medicine, 163(3), 191–204. DOI: 10.7326/M14-2841.
17. Edinger, J. D., Arnedt, J. T., Bertisch, S. M., et al. (2021). Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 17(2), 255–262. DOI: 10.5664/jcsm.8986.
18. Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: a clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125–133. DOI: 10.7326/M15-2175.
19. Riemann, D., Baglioni, C., Bassetti, C., et al. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675–700. DOI: 10.1111/jsr.12594.
20. Espie, C. A., Hames, P., & McKinstry, B. (2013). Use of the internet and mobile media for delivery of cognitive behavioral insomnia therapy. Sleep Medicine Clinics, 8(3), 407–419. DOI: 10.1016/j.jsmc.2013.06.001.
21. Zachariae, R., Lyby, M. S., Ritterband, L. M., & O'Toole, M. S. (2016). Efficacy of internet-delivered cognitive-behavioral therapy for insomnia: a systematic review and meta-analysis of randomized controlled trials. Sleep Medicine Reviews, 30, 1–10. DOI: 10.1016/j.smrv.2015.10.004.
22. Sanger, D. J. (2004). The pharmacology and mechanisms of action of new generation, non-benzodiazepine hypnotic agents. CNS Drugs, 18(Suppl 1), 9–15. DOI: 10.2165/00023210-200418001-00003.
23. FDA Drug Safety Communication. (2013). FDA requires lower recommended doses for certain drugs containing zolpidem.
24. Mignot, E. (2013). Pharmacology and pharmacokinetics of hypnotic medications. Sleep Medicine Clinics, 8(3), 365–376. DOI: 10.1016/j.jsmc.2013.05.012.
25. De Crescenzo, F., D'Alò, G. L., Ostinelli, E. G., et al. (2022). Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis. Lancet, 400(10347), 170–184. DOI: 10.1016/S0140-6736(22)00878-9.
26. Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017). Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 13(2), 307–349. DOI: 10.5664/jcsm.6470.
27. Scammell, T. E., & Winrow, C. J. (2011). Orexin receptors: pharmacology and therapeutic opportunities. Annual Review of Pharmacology and Toxicology, 51, 243–266. DOI: 10.1146/annurev-pharmtox-010510-100528.
28. Norman, J. L., & Anderson, S. L. (2016). Novel class of medications, orexin receptor antagonists, in the treatment of insomnia. Nature and Science of Sleep, 8, 239–247. DOI: 10.2147/NSS.S76910.
29. Herring, W. J., Connor, K. M., Snyder, E., et al. (2016). Suvorexant in patients with insomnia: pooled analyses of three-month data from phase-3 randomized controlled clinical trials. Journal of Clinical Sleep Medicine, 12(9), 1215–1225. DOI: 10.5664/jcsm.6116.
30. Yardley, J., Kärppä, M., Inoue, Y., et al. (2021). Long-term effectiveness and safety of lemborexant in adults with insomnia disorder: results from a phase 3 randomized clinical trial. Sleep Medicine, 80, 333–342. DOI: 10.1016/j.sleep.2021.01.048.
31. Mignot, E., Mayleben, D., Fietze, I., et al. (2022). Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials. Lancet Neurology, 21(2), 125–139. DOI: 10.1016/S1474-4422(21)00436-1.
32. Mendelson, W. B. (2005). A review of the evidence for the efficacy and safety of trazodone in insomnia. Journal of Clinical Psychiatry, 66(4), 469–476. DOI: 10.4088/jcp.v66n0409.
33. Stahl, S. M. (2009). Mechanism of action of trazodone: a multifunctional drug. CNS Spectrums, 14(10), 536–546. DOI: 10.1017/s1092852900024020.
34. Sigel, E., & Steinmann, M. E. (2012). Structure, function, and modulation of GABA-A receptors. Journal of Biological Chemistry, 287(48), 40224–40231. DOI: 10.1074/jbc.R112.386664.
35. Olfson, M., King, M., & Schoenbaum, M. (2015). Benzodiazepine use in the United States. JAMA Psychiatry, 72(2), 136–142. DOI: 10.1001/jamapsychiatry.2014.1763.
36. Lader, M. (2011). Benzodiazepines revisited — will we ever learn? Addiction, 106(12), 2086–2109. DOI: 10.1111/j.1360-0443.2011.03563.x.
37. FDA Drug Safety Communication. (2016). FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines.
38. Pattinson, K. T. S. (2008). Opioids and the control of respiration. British Journal of Anaesthesia, 100(6), 747–758. DOI: 10.1093/bja/aen094.
39. Sun, E. C., Dixit, A., Humphreys, K., Darnall, B. D., Baker, L. C., & Mackey, S. (2017). Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ, 356, j760. DOI: 10.1136/bmj.j760.
40. Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC guideline for prescribing opioids for chronic pain — United States, 2016. JAMA, 315(15), 1624–1645. DOI: 10.1001/jama.2016.1464.
41. Young, T., Evans, L., Finn, L., & Palta, M. (1997). Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep, 20(9), 705–706. DOI: 10.1093/sleep/20.9.705.
42. Sullivan, C. E., Issa, F. G., Berthon-Jones, M., & Eves, L. (1981). Reversal of obstructive sleep apnoea by continuous positive airway pressure applied through the nares. Lancet, 1(8225), 862–865. DOI: 10.1016/s0140-6736(81)92140-1.
43. Weaver, T. E., & Grunstein, R. R. (2008). Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proceedings of the American Thoracic Society, 5(2), 173–178. DOI: 10.1513/pats.200708-119MG.
44. Sawyer, A. M., Gooneratne, N. S., Marcus, C. L., Ofer, D., Richards, K. C., & Weaver, T. E. (2011). A systematic review of CPAP adherence across age groups. Sleep Medicine Reviews, 15(6), 343–356. DOI: 10.1016/j.smrv.2011.01.003.
45. Eckert, D. J., White, D. P., Jordan, A. S., Malhotra, A., & Wellman, A. (2013). Defining phenotypic causes of obstructive sleep apnea. American Journal of Respiratory and Critical Care Medicine, 188(8), 996–1004. DOI: 10.1164/rccm.201303-0448OC.
46. Eckert, D. J. (2018). Phenotypic approaches to obstructive sleep apnoea. Sleep Medicine Reviews, 37, 45–59. DOI: 10.1016/j.smrv.2016.12.003.
47. Phillips, C. L., Grunstein, R. R., Darendeliler, M. A., et al. (2013). Health outcomes of continuous positive airway pressure versus oral appliance treatment for obstructive sleep apnea: a randomized controlled trial. American Journal of Respiratory and Critical Care Medicine, 187(8), 879–887. DOI: 10.1164/rccm.201212-2223OC.
48. Strollo, P. J., Soose, R. J., Maurer, J. T., et al. (2014). Upper-airway stimulation for obstructive sleep apnea. New England Journal of Medicine, 370(2), 139–149. DOI: 10.1056/NEJMoa1308659.
49. Foster, G. D., Borradaile, K. E., Sanders, M. H., et al. (2009). A randomized study on the effect of weight loss on obstructive sleep apnea among obese patients with type 2 diabetes. Archives of Internal Medicine, 169(17), 1619–1626. DOI: 10.1001/archinternmed.2009.266.
50. Greenhill, L. L., Pliszka, S., Dulcan, M. K., et al. (2002). Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child and Adolescent Psychiatry, 41(2 Suppl), 26S–49S.
51. Boscolo-Berto, R., Viel, G., Montagnese, S., et al. (2012). Narcolepsy and effectiveness of gamma-hydroxybutyrate: a systematic review and meta-analysis of randomized controlled trials. Sleep Medicine Reviews, 16(5), 431–443. DOI: 10.1016/j.smrv.2011.09.001.
52. Dauvilliers, Y., Bassetti, C., Lammers, G. J., et al. (2013). Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurology, 12(11), 1068–1075. DOI: 10.1016/S1474-4422(13)70225-4.
53. Thorpy, M. J., Shapiro, C., Mayer, G., et al. (2019). A randomized study of solriamfetol for excessive sleepiness in narcolepsy. Annals of Neurology, 85(3), 359–370. DOI: 10.1002/ana.25423.
54. Mignot, E., Olfson, M., Brown, P. F., et al. (2024). Orexin receptor agonist development for narcolepsy. Sleep Medicine Reviews, 73, 101848. DOI: 10.1016/j.smrv.2023.101848.
55. American Academy of Sleep Medicine. (2014). International Classification of Sleep Disorders, 3rd Edition. AASM.
56. Drake, C. L., Roehrs, T., Richardson, G., Walsh, J. K., & Roth, T. (2004). Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep, 27(8), 1453–1462. DOI: 10.1093/sleep/27.8.1453.
57. Eastman, C. I., Stewart, K. T., Mahoney, M. P., Liu, L., & Fogg, L. F. (1994). Dark goggles and bright light improve circadian rhythm adaptation to night-shift work. Sleep, 17(6), 535–543. DOI: 10.1093/sleep/17.6.535.
58. Smith, M. R., & Eastman, C. I. (2012). Shift work: health, performance and safety problems, traditional countermeasures, and innovative management strategies to reduce circadian misalignment. Nature and Science of Sleep, 4, 111–132. DOI: 10.2147/NSS.S10372.
59. Czeisler, C. A., Walsh, J. K., Roth, T., et al. (2005). Modafinil for excessive sleepiness associated with shift-work sleep disorder. New England Journal of Medicine, 353(5), 476–486. DOI: 10.1056/NEJMoa041292.
60. Liira, J., Verbeek, J. H., Costa, G., et al. (2014). Pharmacological interventions for sleepiness and sleep disturbances caused by shift work. Cochrane Database of Systematic Reviews, (8), CD009776. DOI: 10.1002/14651858.CD009776.pub2.
61. Driscoll, T. R., Grunstein, R. R., & Rogers, N. L. (2007). A systematic review of the neurobehavioural and physiological effects of shiftwork systems. Sleep Medicine Reviews, 11(3), 179–194. DOI: 10.1016/j.smrv.2006.11.001.
62. International Agency for Research on Cancer. (2010). IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 98: Painting, Firefighting, and Shiftwork. Lyon: IARC.
63. International Agency for Research on Cancer. (2020). IARC Monographs on the Identification of Carcinogenic Hazards to Humans, Volume 124: Night Shift Work. Lyon: IARC.
64. Eastman, C. I., & Burgess, H. J. (2009). How to travel the world without jet lag. Sleep Medicine Clinics, 4(2), 241–255. DOI: 10.1016/j.jsmc.2009.02.006.
65. Eastman, C. I., Gazda, C. J., Burgess, H. J., Crowley, S. J., & Fogg, L. F. (2005). Advancing circadian rhythms before eastward flight: a strategy to prevent or reduce jet lag. Sleep, 28(1), 33–44. DOI: 10.1093/sleep/28.1.33.
66. Burgess, H. J., Crowley, S. J., Gazda, C. J., Fogg, L. F., & Eastman, C. I. (2003). Preflight adjustment to eastward travel: 3 days of advancing sleep with and without morning bright light. Journal of Biological Rhythms, 18(4), 318–328. DOI: 10.1177/0748730403253585.
67. Choy, M., & Salbu, R. L. (2011). Jet lag: current and potential therapies. P & T, 36(4), 221–231.
68. Dubocovich, M. L., Delagrange, P., Krause, D. N., Sugden, D., Cardinali, D. P., & Olcese, J. (2010). International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacological Reviews, 62(3), 343–380. DOI: 10.1124/pr.110.002832.
69. Kato, K., Hirai, K., Nishiyama, K., et al. (2005). Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology, 48(2), 301–310. DOI: 10.1016/j.neuropharm.2004.09.007.
70. Roth, T., Stubbs, C., & Walsh, J. K. (2005). Ramelteon (TAK-375), a selective MT1/MT2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep, 28(3), 303–307. DOI: 10.1093/sleep/28.3.303.
71. Lockley, S. W., Dressman, M. A., Licamele, L., et al. (2015). Tasimelteon for non-24-hour sleep-wake disorder in totally blind people (SET and RESET): two randomised, placebo-controlled, double-masked phase 3 trials. Lancet, 386(10005), 1754–1764. DOI: 10.1016/S0140-6736(15)60031-9.
72. Bonacci, J. M., Venci, J. V., & Gandhi, M. A. (2015). Tasimelteon (Hetlioz): a new melatonin receptor agonist for the treatment of non-24-hour sleep-wake disorder. Journal of Pharmacy Practice, 28(5), 473–478. DOI: 10.1177/0897190015589859.
73. Polymeropoulos, C. M., Mohrman, M. A., Keefe, M. S., et al. (2021). Tasimelteon safely and effectively improves sleep in Smith-Magenis syndrome: a double-blind randomized trial. Journal of Clinical Sleep Medicine, 17(10), 2065–2074. DOI: 10.5664/jcsm.9374.
74. Ferracioli-Oda, E., Qawasmi, A., & Bloch, M. H. (2013). Meta-analysis: melatonin for the treatment of primary sleep disorders. PLOS ONE, 8(5), e63773. DOI: 10.1371/journal.pone.0063773.
75. Erland, L. A. E., & Saxena, P. K. (2017). Melatonin natural health products and supplements: presence of serotonin and significant variability of melatonin content. Journal of Clinical Sleep Medicine, 13(2), 275–281. DOI: 10.5664/jcsm.6462.
76. Rosenthal, N. E., Sack, D. A., Gillin, J. C., et al. (1984). Seasonal affective disorder. A description of the syndrome and preliminary findings with light therapy. Archives of General Psychiatry, 41(1), 72–80. DOI: 10.1001/archpsyc.1984.01790120076010.
77. Terman, M., & Terman, J. S. (2005). Light therapy for seasonal and nonseasonal depression: efficacy, protocol, safety, and side effects. CNS Spectrums, 10(8), 647–663. DOI: 10.1017/s1092852900019611.
78. Golden, R. N., Gaynes, B. N., Ekstrom, R. D., et al. (2005). The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. American Journal of Psychiatry, 162(4), 656–662. DOI: 10.1176/appi.ajp.162.4.656.
79. Pjrek, E., Friedrich, M.-E., Cambioli, L., et al. (2020). The efficacy of light therapy in the treatment of seasonal affective disorder: a meta-analysis of randomized controlled trials. Psychotherapy and Psychosomatics, 89(1), 17–24. DOI: 10.1159/000502891.
80. Lam, R. W., Levitt, A. J., Levitan, R. D., et al. (2016). Efficacy of bright light treatment, fluoxetine, and the combination in patients with nonseasonal major depressive disorder: a randomized clinical trial. JAMA Psychiatry, 73(1), 56–63. DOI: 10.1001/jamapsychiatry.2015.2235.
81. Wirz-Justice, A., Benedetti, F., & Terman, M. (2013). Chronotherapeutics for Affective Disorders: A Clinician's Manual for Light and Wake Therapy (2nd ed.). Karger.
82. Saxvig, I. W., Wilhelmsen-Langeland, A., Pallesen, S., Vedaa, O., Nordhus, I. H., & Bjorvatn, B. (2014). Prevalence and correlates of delayed sleep phase in high school students. Sleep Medicine, 15(2), 247–254. DOI: 10.1016/j.sleep.2013.10.014.
83. Burgess, H. J., Revell, V. L., Molina, T. A., & Eastman, C. I. (2010). Human phase response curves to three days of daily melatonin: 0.5 mg versus 3.0 mg. Journal of Clinical Endocrinology and Metabolism, 95(7), 3325–3331. DOI: 10.1210/jc.2009-2590.
84. Auger, R. R., Burgess, H. J., Emens, J. S., et al. (2015). Clinical practice guideline for the treatment of intrinsic circadian rhythm sleep-wake disorders. Journal of Clinical Sleep Medicine, 11(10), 1199–1236. DOI: 10.5664/jcsm.5100.
85. Morgenthaler, T. I., Auerbach, S., Casey, K. R., et al. (2018). Position paper for the treatment of nightmare disorder in adults. Journal of Clinical Sleep Medicine, 14(6), 1041–1055. DOI: 10.5664/jcsm.7178.
86. Solt, L. A., Wang, Y., Banerjee, S., et al. (2012). Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature, 485(7396), 62–68. DOI: 10.1038/nature11030.
87. Hirota, T., Lee, J. W., St John, P. C., et al. (2012). Identification of small molecule activators of cryptochrome. Science, 337(6098), 1094–1097. DOI: 10.1126/science.1223710.
88. Scheer, F. A. J. L., Hilton, M. F., Mantzoros, C. S., & Shea, S. A. (2009). Adverse metabolic and cardiovascular consequences of circadian misalignment. PNAS, 106(11), 4453–4458. DOI: 10.1073/pnas.0808180106.
89. Panda, S. (2016). Circadian physiology of metabolism. Science, 354(6315), 1008–1015. DOI: 10.1126/science.aah4967.
90. Hirshkowitz, M., Whiton, K., Albert, S. M., et al. (2015). National Sleep Foundation's sleep time duration recommendations: methodology and results summary. Sleep Health, 1(1), 40–43. DOI: 10.1016/j.sleh.2014.12.010.
91. Watson, N. F., Badr, M. S., Belenky, G., et al. (2015). Recommended amount of sleep for a healthy adult: a joint consensus statement of the American Academy of Sleep Medicine and Sleep Research Society. Sleep, 38(6), 843–844. DOI: 10.5665/sleep.4716.
92. Liu, Y., Wheaton, A. G., Chapman, D. P., Cunningham, T. J., Lu, H., & Croft, J. B. (2016). Prevalence of healthy sleep duration among adults — United States, 2014. MMWR, 65(6), 137–141. DOI: 10.15585/mmwr.mm6506a1.
93. Hale, L., & Do, D. P. (2007). Racial differences in self-reports of sleep duration in a population-based study. Sleep, 30(9), 1096–1103. DOI: 10.1093/sleep/30.9.1096.
94. Grandner, M. A., Williams, N. J., Knutson, K. L., Roberts, D., & Jean-Louis, G. (2016). Sleep disparity, race/ethnicity, and socioeconomic position. Sleep Medicine, 18, 7–18. DOI: 10.1016/j.sleep.2015.01.020.
95. Jackson, C. L., Walker, J. R., Brown, M. K., Das, R., & Jones, N. L. (2020). A workshop report on the causes and consequences of sleep health disparities. Sleep, 43(8), zsaa037. DOI: 10.1093/sleep/zsaa037.
96. Wheaton, A. G., Olsen, E. O., Miller, G. F., & Croft, J. B. (2016). Sleep duration and injury-related risk behaviors among high school students — United States, 2007–2013. MMWR, 65(13), 337–341. DOI: 10.15585/mmwr.mm6513a1.
97. Cappuccio, F. P., Cooper, D., D'Elia, L., Strazzullo, P., & Miller, M. A. (2011). Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. European Heart Journal, 32(12), 1484–1492. DOI: 10.1093/eurheartj/ehr007.
98. Itani, O., Jike, M., Watanabe, N., & Kaneita, Y. (2017). Short sleep duration and health outcomes: a systematic review, meta-analysis, and meta-regression. Sleep Medicine, 32, 246–256. DOI: 10.1016/j.sleep.2016.08.006.
99. Daghlas, I., Dashti, H. S., Lane, J., et al. (2019). Sleep duration and myocardial infarction. Journal of the American College of Cardiology, 74(10), 1304–1314. DOI: 10.1016/j.jacc.2019.07.022.
100. Dashti, H. S., Jones, S. E., Wood, A. R., et al. (2019). Genome-wide association study identifies genetic loci for self-reported habitual sleep duration supported by accelerometer-derived estimates. Nature Communications, 10, 1100. DOI: 10.1038/s41467-019-08917-4.
101. Straif, K., Baan, R., Grosse, Y., et al. (2007). Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncology, 8(12), 1065–1066. DOI: 10.1016/S1470-2045(07)70373-X.
102. IARC Monographs Vol 124 group. (2019). Carcinogenicity of night shift work. Lancet Oncology, 20(8), 1058–1059. DOI: 10.1016/S1470-2045(19)30455-3.
103. Travis, R. C., Balkwill, A., Fensom, G. K., et al. (2016). Night shift work and breast cancer incidence: three prospective studies and meta-analysis of published studies. Journal of the National Cancer Institute, 108(12), djw169. DOI: 10.1093/jnci/djw169.
104. Wegrzyn, L. R., Tamimi, R. M., Rosner, B. A., et al. (2017). Rotating night-shift work and the risk of breast cancer in the Nurses' Health Studies. American Journal of Epidemiology, 186(5), 532–540. DOI: 10.1093/aje/kwx140.
105. Wise, J. (2009). Danish night shift workers with breast cancer awarded compensation. BMJ, 338, b1152. DOI: 10.1136/bmj.b1152.
106. Wahlstrom, K. (2002). Changing times: findings from the first longitudinal study of later high school start times. NASSP Bulletin, 86(633), 3–21. DOI: 10.1177/019263650208663302.
107. Wahlstrom, K., Dretzke, B., Gordon, M., Peterson, K., Edwards, K., & Gdula, J. (2014). Examining the Impact of Later School Start Times on the Health and Academic Performance of High School Students: A Multi-Site Study. Center for Applied Research and Educational Improvement, University of Minnesota.
108. Adolescent Sleep Working Group, Committee on Adolescence, & Council on School Health. (2014). School start times for adolescents. Pediatrics, 134(3), 642–649. DOI: 10.1542/peds.2014-1697.
109. California State Legislature. (2019). Senate Bill 328: Pupil attendance: school start time.
110. Owens, J. A., Belon, K., & Moss, P. (2010). Impact of delaying school start time on adolescent sleep, mood, and behavior. Archives of Pediatrics & Adolescent Medicine, 164(7), 608–614. DOI: 10.1001/archpediatrics.2010.96.
111. Baglioni, C., Battagliese, G., Feige, B., et al. (2011). Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies. Journal of Affective Disorders, 135(1–3), 10–19. DOI: 10.1016/j.jad.2011.01.011.
112. Hertenstein, E., Feige, B., Gmeiner, T., et al. (2019). Insomnia as a predictor of mental disorders: a systematic review and meta-analysis. Sleep Medicine Reviews, 43, 96–105. DOI: 10.1016/j.smrv.2018.10.006.
113. Carney, C. E., Edinger, J. D., Olsen, M. K., Stechuchak, K. M., Krystal, A. D., & Wyatt, J. K. (2010). Inter-rater reliability for insomnia diagnoses derived from the Duke Structured Interview for Sleep Disorders. Sleep Medicine, 11(4), 343–347. DOI: 10.1016/j.sleep.2009.07.018.
114. Pigeon, W. R., Pinquart, M., & Conner, K. (2012). Meta-analysis of sleep disturbance and suicidal thoughts and behaviors. Journal of Clinical Psychiatry, 73(9), e1160–e1167. DOI: 10.4088/JCP.11r07586.
115. Bernert, R. A., Kim, J. S., Iwata, N. G., & Perlis, M. L. (2015). Sleep disturbances as an evidence-based suicide risk factor. Current Psychiatry Reports, 17(3), 554. DOI: 10.1007/s11920-015-0554-4.
116. Manber, R., Edinger, J. D., Gress, J. L., San Pedro-Salcedo, M. G., Kuo, T. F., & Kalista, T. (2008). Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. Sleep, 31(4), 489–495. DOI: 10.1093/sleep/31.4.489.
117. Trockel, M., Karlin, B. E., Taylor, C. B., Brown, G. K., & Manber, R. (2015). Effects of cognitive behavioral therapy for insomnia on suicidal ideation in veterans. Sleep, 38(2), 259–265. DOI: 10.5665/sleep.4410.
118. Irwin, M. R. (2019). Sleep and inflammation: partners in sickness and in health. Nature Reviews Immunology, 19(11), 702–715. DOI: 10.1038/s41577-019-0190-z.
119. Tefft, B. C. (2012). Prevalence of motor vehicle crashes involving drowsy drivers, United States, 1999–2008. Accident Analysis & Prevention, 45, 180–186. DOI: 10.1016/j.aap.2011.05.028.
120. Tefft, B. C. (2014). Prevalence of motor vehicle crashes involving drowsy drivers, United States, 2009–2013. AAA Foundation for Traffic Safety.
121. AAA Foundation for Traffic Safety. (2023). 2022 Traffic Safety Culture Index Annual Report.
122. Williamson, A. M., & Feyer, A. M. (2000). Moderate sleep deprivation produces impairments in cognitive and motor performance equivalent to legally prescribed levels of alcohol intoxication. Occupational and Environmental Medicine, 57(10), 649–655. DOI: 10.1136/oem.57.10.649.
123. Ohayon, M. M., Carskadon, M. A., Guilleminault, C., & Vitiello, M. V. (2004). Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals. Sleep, 27(7), 1255–1273. DOI: 10.1093/sleep/27.7.1255.
124. Mander, B. A., Winer, J. R., & Walker, M. P. (2017). Sleep and human aging. Neuron, 94(1), 19–36. DOI: 10.1016/j.neuron.2017.02.004.
125. Bliwise, D. L. (1993). Sleep in normal aging and dementia. Sleep, 16(1), 40–81. DOI: 10.1093/sleep/16.1.40.
126. Duffy, J. F., Zitting, K. M., & Chinoy, E. D. (2015). Aging and circadian rhythms. Sleep Medicine Clinics, 10(4), 423–434. DOI: 10.1016/j.jsmc.2015.08.002.
127. By the 2019 American Geriatrics Society Beers Criteria Update Expert Panel. (2019). American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics Society, 67(4), 674–694. DOI: 10.1111/jgs.15767.
128. Iliff, J. J., Wang, M., Liao, Y., et al. (2012). A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Science Translational Medicine, 4(147), 147ra111. DOI: 10.1126/scitranslmed.3003748.
129. Xie, L., Kang, H., Xu, Q., et al. (2013). Sleep drives metabolite clearance from the adult brain. Science, 342(6156), 373–377. DOI: 10.1126/science.1241224.
130. Mestre, H., Mori, Y., & Nedergaard, M. (2020). The brain's glymphatic system: current controversies. Trends in Neurosciences, 43(7), 458–466. DOI: 10.1016/j.tins.2020.04.003.
131. Plog, B. A., & Nedergaard, M. (2018). The glymphatic system in central nervous system health and disease: past, present, and future. Annual Review of Pathology, 13, 379–394. DOI: 10.1146/annurev-pathol-051217-111018.
132. Smith, A. J., & Verkman, A. S. (2018). The "glymphatic" mechanism for solute clearance in Alzheimer's disease: game changer or unproven speculation? FASEB Journal, 32(2), 543–551. DOI: 10.1096/fj.201700999.
133. Lucey, B. P., Wisch, J., Boerwinkle, A. H., et al. (2021). Sleep and longitudinal cognitive performance in preclinical and early symptomatic Alzheimer's disease. Brain, 144(9), 2852–2862. DOI: 10.1093/brain/awab272.
134. Papalambros, N. A., Santostasi, G., Malkani, R. G., et al. (2017). Acoustic enhancement of sleep slow oscillations and concomitant memory improvement in older adults. Frontiers in Human Neuroscience, 11, 109. DOI: 10.3389/fnhum.2017.00109.
135. Wunderlin, M., Züst, M. A., Hertenstein, E., et al. (2021). Modulating overnight memory consolidation by acoustic stimulation during slow-wave sleep: a systematic review and meta-analysis. Sleep, 44(7), zsaa296. DOI: 10.1093/sleep/zsaa296.
136. Kang, J. E., Lim, M. M., Bateman, R. J., et al. (2009). Amyloid-β dynamics are regulated by orexin and the sleep-wake cycle. Science, 326(5955), 1005–1007. DOI: 10.1126/science.1180962.
137. Roh, J. H., Jiang, H., Finn, M. B., et al. (2014). Potential role of orexin and sleep modulation in the pathogenesis of Alzheimer's disease. Journal of Experimental Medicine, 211(13), 2487–2496. DOI: 10.1084/jem.20141788.
138. Lucey, B. P., Hicks, T. J., McLeland, J. S., et al. (2018). Effect of sleep on overnight cerebrospinal fluid amyloid β kinetics. Annals of Neurology, 83(1), 197–204. DOI: 10.1002/ana.25117.
139. Spira, A. P., Gamaldo, A. A., An, Y., et al. (2013). Self-reported sleep and β-amyloid deposition in community-dwelling older adults. JAMA Neurology, 70(12), 1537–1543. DOI: 10.1001/jamaneurol.2013.4258.
140. Ju, Y. S., Ooms, S. J., Sutphen, C., et al. (2017). Slow wave sleep disruption increases cerebrospinal fluid amyloid-β levels. Brain, 140(8), 2104–2111. DOI: 10.1093/brain/awx148.
141. Livingston, G., Huntley, J., Liu, K. Y., et al. (2024). Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet, 404(10452), 572–628. DOI: 10.1016/S0140-6736(24)01296-0.
142. Schenck, C. H., Bundlie, S. R., Ettinger, M. G., & Mahowald, M. W. (1986). Chronic behavioral disorders of human REM sleep, a new category of parasomnia. Sleep, 9(2), 293–308. DOI: 10.1093/sleep/9.2.293.
143. Postuma, R. B., Iranzo, A., Hu, M., et al. (2019). Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain, 142(3), 744–759. DOI: 10.1093/brain/awz030.
144. Janzen, A., Vadasz, D., Booij, J., et al. (2022). Progressive olfactory impairment and cardiac sympathetic denervation in REM sleep behavior disorder. Journal of Parkinson's Disease, 12(7), 1989–1998. DOI: 10.3233/JPD-223273.
145. Stevens, R. G. (1987). Electric power use and breast cancer: a hypothesis. American Journal of Epidemiology, 125(4), 556–561. DOI: 10.1093/oxfordjournals.aje.a114569.
146. Stevens, R. G., Brainard, G. C., Blask, D. E., Lockley, S. W., & Motta, M. E. (2014). Breast cancer and circadian disruption from electric lighting in the modern world. CA: A Cancer Journal for Clinicians, 64(3), 207–218. DOI: 10.3322/caac.21218.
147. Sancar, A., Lindsey-Boltz, L. A., Kang, T.-H., Reardon, J. T., Lee, J. H., & Ozturk, N. (2010). Circadian clock control of the cellular response to DNA damage. FEBS Letters, 584(12), 2618–2625. DOI: 10.1016/j.febslet.2010.03.017.
148. Lévi, F., Okyar, A., Dulong, S., Innominato, P. F., & Clairambault, J. (2010). Circadian timing in cancer treatments. Annual Review of Pharmacology and Toxicology, 50, 377–421. DOI: 10.1146/annurev.pharmtox.48.113006.094626.
149. Innominato, P. F., Karaboué, A., Focan, C., et al. (2020). Efficacy and safety of chronomodulated irinotecan, oxaliplatin, 5-fluorouracil and leucovorin combination as first- or second-line treatment against metastatic colorectal cancer: results from the International EORTC 05011 Trial. International Journal of Cancer, 148(10), 2512–2521. DOI: 10.1002/ijc.33422.
150. Berry, R. B., Quan, S. F., Abreu, A. R., et al. (2020). The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, Version 2.6. American Academy of Sleep Medicine.